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Background:	 Adolescent	 girls	 and	 young	 women	 (AGYW)	 are	 at	 high	 risk	 for	 HIV	infection,	 particularly	 in	 Southern	 Africa.	 In	 addition,	 some	 hormonal	 contraceptives	(HC),	 such	 as	progestin	 only-injectable	 contraceptives	 DMPA	 and	NET-EN,	 have	 been	associated	with	 significantly	 increased	 risk	 for	HIV	 infection.	 These	HC	 together	with	sexual	 immaturity	may	 increase	activation	of	CD4+	T	cells	 in	 the	 female	 reproductive	tract	 (FRT),	 which	 are	 target	 cells	 for	 HIV	 infection.	 NuvaRing,	 also	 a	 long-acting	progestin-containing	contraceptive	albeit	topical,	has	recently	been	introduced	to	South	Africa,	and	may	offer	an	improved	safety	profile	over	NET-EN	and	DMPA	in	terms	of	HIV	risk	 for	 young	women.	 Recently,	 Th17	 cells	 have	 been	 found	 to	 be	 disproportionally	susceptible	to	HIV	infection	compared	to	the	other	T	helper	subsets	although	the	impact	of	HC	use	 on	Th17	 cell	 frequency	 and	 activation	 has	 not	 been	 investigated.	Here,	 the	impact	 of	 NuvaRing,	 NET-EN	 and	 combined	 oral	 contraceptive	 pills	 (COCPs)	 on	 the	vaginal	microenvironment	of	the	FRT	in	AGYW	was	investigated	as	this	relates	to	HIV	risk,	 with	 particular	 focus	 on	 cervical	 Th17	 cells	 and	 their	 related	 cytokines	 (Th17-related	cytokines).	
	
Methods:	One	hundred	and	thirty	HIV-negative	adolescent	girls	between	the	age	of	15	and	19	years	were	enrolled	 into	a	 randomized,	 controlled	crossover	 study	comparing	NuvaRing	 (n=45),	 NET-EN	 (n=45),	 and	 COCPs	 (n=40)	 for	 16	 weeks	 (~4	 menstrual	cycles).	 At	 crossover	 (16	 weeks),	 the	 AGYW	 changed	 to	 another	 method	 for	 the	following	 16	 weeks:	 23	 of	 those	 who	 used	 NuvaRing	 changed	 to	 NET-EN	 while	 8	changed	 to	 COCPs;	 23	 of	 those	 who	 used	 NET-EN	 and	 24	 of	 those	 who	 used	 COCPs	changed	 to	 NuvaRing.	 The	 protocol	 included	 three	 study	 visits	 in	 total	 (screening,	crossover,	study	completion	visits).	Of	the	130	adolescents	enrolled,	107/130	reached	the	 crossover	 visit	 and	 92/130	 reached	 the	 study	 exit	 visit.	 All	 adolescents	 were	screened	 for	 STIs	 (multiplex	 PCR	 for	 Chlamydia	 trachomatis,	 Neisseria	 gonorrhoeae,	




collected,	including	Digene	cervical	cytobrushes	(for	flow	cytometry	of	cervical	T	cells)	and	 menstrual	 cups	 at	 each	 study	 visit	 (for	 measurement	 of	 genital	 cytokine	concentrations).	 Multiparameter	 flow	 cytometry	 was	 performed	 on	 cytobrushes	 to	determine	 the	 frequency	 and	 activation	 status	 (CD38	 and	 HLA-DR)	 of	 Th17	 cells	(defined	 by	 expression	 of	 CCR6+CCR10-),	 total	 CD3+CD4+	 T	 cells	 and	 CD3+CD8+	including	Tc17	cells	 (CD8+	CCR6+).	A	panel	of	 fifteen	Th17-related	cytokines	(IL-17A,	IL-17F,	IL-21,	IL-22,	IL-6,	IL-1β,	IL-23,	IL-33,	TNF-α,	IL-4,	IL-10,	IL-25,	IL-31,	IFN-γ	and	sCD40L)	were	measured	in	genital	secretions	by	Luminex.	Results	have	been	presented	as	an	intention	to	treat	(ITT)	and	per	protocol	(PP;	which	accounted	for	early	switching	of	 HC	 products	 prior	 to	 the	 crossover	 visit).	 Unless	 otherwise	 stated,	 all	 statistical	testing	 was	 non-parametric,	 and	 P≤0.05	 were	 considered	 significant.	 The	 Benjamini-Hochberg	method	was	used	to	adjust	for	multiple	comparisons.	
	
Results:	 In	 the	 FRT	 of	 adolescents	 at	 baseline	 (before	 randomization),	 Th17	 cells	(CCR6+CCR10-)	were	found	to	be	the	major	CD4+	T	cell	subset	in	cytobrushes	(median	54.4%,	 IQR	 43.7%	 -	 64.3%)	 compared	 to	 CCR6-CCR10-	 (median	 42.2%,	 IQR	 33.5%	 -	52.6%),	 CCR6+CCR10+	 (median	 1.2%,	 IQR	 0.4%	 -	 2.8%)	 and	 CCR6-CCR10+	 (median	0.8%,	IQR	0.2%	-	1.9%).	Higher	frequencies	of	Th17	cells	expressed	CCR5	compared	to	CCR6-CCR10-	CD4+	T	cells	(median	68.0%	vs	56.2%	respectively,	p<0.0001).	However,	Th17	 cell	 frequencies	 did	 not	 correlate	 with	 genital	 tract	 Th17-related	 cytokines	 at	baseline.	The	presence	of	BV	or	STIs	did	not	appear	to	influence	either	the	frequencies	or	activation	status	of	cervical	Th17	cells.	Although	BV	(Nugent	7-10)	and	having	a	non-




p=0.03,	 respectively),	 which	 was	 not	 evident	 in	 those	 using	 COCPs.	 Furthermore,	adolescents	 using	 NuvaRing	 had	 reduced	 frequencies	 of	 Th17	 cells	 compared	 to	baseline	(p=0.001),	which	was	not	evident	in	those	using	NET-EN	or	COCPs.	Although	it	was	 hypothesized	 that	 NuvaRing	would	 offer	 some	 safety	 advantage	 over	 NET-EN	 in	terms	 of	 mucosal	 HIV	 target	 cell	 activation,	 intra-individual	 analysis	 showed	 a	significant	 increase	 in	 the	 frequency	 of	 highly	 activated	 cervical	 Th17	 cells	 in	 those	adolescents	 who	 started	 using	 the	 ring.	 A	 significant	 increase	 in	 genital	 tract	concentrations	of	several	Th17-related	cytokine	concentrations	(including	IL-21,	IL-1β,	IL-33,	TNF-α,	 IL-4,	 IFN-γ	and	sCD40L)	was	noted	in	adolescents	assigned	to	NuvaRing	after	16	weeks	of	use,	suggesting	that	the	presence	of	the	vaginal	ring	likely	increased	genital	cytokine	responses.	Although	the	frequency	and	activation	of	CD8+	T	cells	was	similar	 across	 HC	 arm,	 intra-individual	 analysis	 showed	 changes	 in	 the	 frequency	 of	activation	markers	on	CD8+	T	cells	in	all	HC	arms.	Moreover,	frequencies	of	Tc17	cells	were	 significantly	 reduced	 after	 4	 months	 of	 contraceptive	 use	 in	 each	 HC	 arm	compared	to	baseline	frequencies.	
	










Despite	 some	 remarkable	 advances	 in	 treatment	 and	 more	 modest	 advances	 in	prevention,	 HIV-1	 continues	 to	 be	 a	 global	 epidemic	 and	 AIDS	 has	 claimed	 an	estimated	35	million	lives.	By	the	end	of	2016,	UNAIDS	estimated	that	around	40	million	 people	were	HIV-infected,	 and	 1.8	million	 people	 became	newly	 infected	globally	(UNAIDS,	2017).	While	HIV	is	a	global	health	emergency,	African	countries	bear	the	highest	burden,	with	approximately	19	million	people	in	this	region	living	with	HIV,	and	approximately	7	million	are	living	in	South	Africa	(SA).	Sub-Saharan	Africa	(SSA)	accounts	for	about	43%	of	the	global	total	new	infections.	The	scale	up	of	 antiretroviral	 therapy	 (ART)	 in	 eastern	 and	 southern	 Africa,	 together	 with	improved	 public	 health	 measures	 such	 as	 male	 circumcision	 programs,	 have	contributed	 to	a	decline	of	up	 to	29%	of	new	 infections	between	2010	and	2016	(UNAIDS,	 2017).	 In	 lower	 HIV	 prevalence	 settings,	 the	 key	 risk	 populations	continue	 being	men	who	 have	 sex	with	men	 (MSM),	 sex	workers,	 prisoners	 and	injectable	 drug	 users.	 In	 high-prevalence	 settings,	 adolescent	 girls	 and	 young	women	(AGYW)	between	the	ages	of	15-24	are	the	key	risk	population,	with	80%	of	 young	women	who	become	 infected	 residing	 in	 SSA.	 Even	 in	 the	 era	 of	ARTs,	AIDS-related	 illness	remains	 the	second	 leading	cause	of	death	among	women	of	reproductive	 age	 in	Africa	 because	 of	 poor	 access	 to	 or	 uptake	 of	HIV	 screening	and/or	drugs	(UNAIDS,	2017).		This	dissertation	will	focus	on	HIV-1	risk	factors	in	AGYW	living	in	Southern	Africa.		
1.2 Sub-Saharan	African	young	women	and	HIV	risk	




(Kharsany	and	Karim,	2016).	Like	countries	within	SSA,	the	gender	discrepancy	in	HIV	 prevalence	 is	 observed	 across	many	 African	 countries.	 South	 Africa	 has	 the	highest	 HIV	 prevalence	 amongst	 15-24	 year	 old	 females	 (13%)	 and	 the	 largest	gender	discrepancy	(difference	of	9%;	Dellar	et	al.,	2015).	Figure	1.1	summarizes	the	prevalence	of	HIV	according	to	gender	in	southern	African	countries.			
	
Figure	 1.1.	 HIV	 prevalence	 in	 selected	 Southern	 African	 countries	 among	 females	
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marriage	(Wadesango	et	al.,	2011;	Lilian	et	al.,	2015).	Moreover,	the	illegal	cultural	practice	of	genital	 female	mutilation	that	are	practiced	 in	some	African	countries	have	 been	 associated	with	 increased	 risk	 for	HIV	 transmission	 (Olaniran,	 2013).	Other	 cultural	 practices	 that	 may	 influence	 HIV	 acquisition	 within	 the	 African	continent	include	polygamy	and	the	practice	of	dry	sex	(Mswela,	2009;	Ramjee	and	Daniels,	2013).		Poverty	has	also	been	suggested	as	an	important	driver	of	HIV	risk	in	women,	as	some	 resort	 to	 transactional	 sex	 (Muula,	 2008).	 Young	 girls	 from	socioeconomically	deprived	families	are	sometimes	forced	or	coerced	into	having	sexual	 relationships	 with	 older	 men,	 also	 known	 as	 “blessers”	 in	 South	 Africa	(Mampane,	2018).	As	a	function	of	the	age	and	economic	disparity	between	young	girls	and	their	older	partners,	the	AGYW	cannot	negotiate	safe	sex	options.	Other	behavioral	factors	(like	alcohol	consumption	and	drug	abuse,	unprotected	sex	and	early	 sexual	 debut)	 or	 cleansing	 and	 sexual	 practices	 (like	 vaginal	 cleansing	 or	douching,	or	use	of	sex	enhancers	inserted	into	the	vagina)	have	also	been	shown	to	 increase	 women’s	 risk	 for	 HIV	 infection	 (Muula,	 2008;	 Ramjee	 and	 Daniels,	2013,	 Idele	 et	 al.,	 2014).	 Due	 to	 the	 high	 prevalence	 of	HIV	 in	 SSA,	 these	 young	women	 are	 likely	 to	 be	 exposed	 frequently	 to	 HIV,	 making	 them	 a	 highly	susceptible	group.			
1.3 Structure	and	immunity	of	the	female	reproductive	tract	



















Although	it	was	generally	thought	that	HIV	infection	of	CD4+	cells	within	the	FRT	occurs	 through	 the	 vagina,	 ectocervix	 or	 endocervix	 (Shen	 et	 al.,	 2012),	 more	recent	evidence	suggests	that	this	can	happen	throughout	the	FRT,	including	CD4+	T	 cells	 resident	 in	 the	 ovaries	 and	 the	 fallopian	 tubes	 (Stieh	 et	 al.,	 2014,	 2016).	Experiments	 in	 macaques	 have	 suggested	 that	 vaginal	 SIV	 infection	 can	 be	mediated	by	both	cell-free	and	cell-associated	viruses	(Hladik	and	McElrath,	2008;	Barreto-de-souza	 et	 al.,	 2014;	Kolodkin-Gal	 et	 al.,	 2013),	 although	 little	 evidence	exists	for	the	latter.			HIV	has	been	proposed	to	cross	the	FRT	mucosal	barrier	through	micro-abrasions	in	the	FRT	squamous	epithelium,	allowing	direct	infection	of	sub-mucosal	CD4+	T	cells,	or	via	transcytosis	of	the	virus	across	the	columnar	epithelium	of	the	upper	FRT	 (Nguyen	 et	 al.,	 2014).	 Other	mechanisms	 that	 have	 been	 suggested	 include	diffusive	percolation	in	the	squamous	epithelium	(Zhang	et	al.,	1999;	Carias	et	al.,	2016).	Following	entry,	HIV	gains	access	to	CD4+	immune	cells	like	macrophages,	DCs,	 Langerhans	 cells	 and	 T	 cells	 (Shattock	 and	 Moore,	 2003).	 HIV	 primarily	establishes	 infection,	 following	sexual	exposure,	 through	CD4+	T	cells	expressing	chemokine	 receptor	CCR5	 (Berges	et	 al.,	 2008;	Grivel	 et	 al.,	 2010).	HIV	has	been	shown	to	infect	and	replicate	in	sub-epithelial	CD4+	mononuclear	cells,	after	which	these	 traffic	 to	 draining	 lymph	 nodes	 and	 subsequently	 are	 thought	 to	 spread	systemically	(Haase,	2011;	Shen	et	al.,	2012).			
1.4 Th17	cells	and	Th17-related	cytokines	








have	similar	biological	functions	(Ishigame	et	al.,	2009;	Ouyang	et	al.,	2012).	Both	of	these	IL-17	cytokines	induce	production	of	IL-6,	several	chemokines	(like	CXCL1	[GRO-1],	 CXCL2	 [macrophage	 inflammatory	 protein	 {MIP}-2a],	 and	 CXCL5	[epithelial-derived	 neutrophil-activating	 {ENA}	 peptide	 78])	 and	 cytokines	including	 granulocyte	 stimulating	 factors	 (granulocyte	 colony	 stimulating	 factor	[G-CSF],	 granulocyte/macrophage	 colony	 stimulating	 factors	 [GM-CSF]).	 The	released	 cytokines	 and	 chemokines	 promote	 different	 functions	 including	 the	activation	and	migration	of	neutrophils	to	sites	of	inflammation	(Bradley	Forlow	et	al.,	2001;	Miyamoto	et	al.,	2003).	IL-17A	and	IL-17F	also	induce	AMPs	production	including	lipocalin	and	the	β-defensins	that	prevent	infection	at	mucosal	surfaces	(Liang	et	al.,	2006;	Aujla	et	al.,	2008;	Monteleone	et	al.,	2011).	Both	are	important	for	 the	 clearance	 of	 extracellular	 bacteria	 such	 as	 Staphylococcus	 aureus	 and	







with	 Th17	 cells.	 Naïve	 CD4+	 T	 cells	 are	 primed	 by	 a	 combination	 of	 cytokines	 to	differentiate	into	Th17	cells	(including	TGF-β,	IL-6,	IL-1β,	IL-21,	IL-23,	IL-33,	and	sCD40L).	IL-21,	IL-1β	and	IL-23	further	promote	expansion,	maintenance	and	survival	of	Th17	cells.	Differentiation	can	be	inhibited	by	IL-25,	IL-4	and	IFN-γ	that	favor	Th2	and	Th1	responses,	respectively.	 Th17	 cells	 directly	 produce	 IL-17A,	 IL-17F,	 IL-21	 and	 IL-22,	 and	 the	production	of	 these	cytokines	can	be	directly	 inhibited	by	IL-10.	Figure	drawn	by	Iyaloo	Konstantinus.			
1.4.1 The	role	of	Th17	cells	at	mucosal	surfaces	







































needed	to	maintain	the	mucosal	barrier	integrity	(Blaschitz	and	Raffatellu,	2010),	and	 loss	 of	 Th17	 cells	 have	 been	 linked	 with	 compromised	 mucosal	 barrier	integrity	(Kanwar	et	al.,	2010;	Hartigan-O’Connor	et	al.,	2011;	He	et	al.,	2011).	IL-17-producing	cells	are	abundant	in	lamina	propria	of	the	small	intestine	(Ivanov	et	al.,	2008).	AMPs,	like	defensins,	are	induced	through	signaling	pathways	triggered	by	IL-17A	and	IL-17F	at	the	intestinal	mucosal	surface,	which	have	been	shown	to	protect	mice	against	enteric	infections	caused	by	bacteria	(Rubino	et	al.,	2012).	In	the	lungs,	 IL-17	is	 important	 in	protection	against	airborne	diseases,	with	IL-17A	playing	a	role	in	the	defense	against	extracellular	pathogens	such	as	Pseudomonas	
aeruginosa	and	Klebsiella	pneumoniae	in	the	airways	(Ye	et	al.,	2001;	Kudva	et	al.,	2011).	 In	 the	 oral	 mucosa,	 Th17	 cells	 and	 IL-17	 receptor	 signaling	 has	 been	identified	 to	 be	 important	 in	 defense	 against	 oral	 candidiasis	 (Conti	 and	 Gaffen,	2010).			In	the	genital	tract,	Th17	immunity	in	mice	has	been	shown	to	play	an	important	role	 in	 protection	 against	 fungal	 and	 bacterial	 infections	 including	 chlamydia,	gonorrhoea	and	candida	(Feinen	et	al.,	2010;	Pietrella	et	al.,	2011;	Gladiator	et	al.,	2013;	 Conti	 and	 Gaffen,	 2015;	 Vicetti	 Miguel	 et	 al.,	 2016).	 Ex	vivo	 studies	 using	human	T	cells	showed	that	C.	albicans	primed	Th17	cells	produce	IL-17	and	IFN-γ	under	 the	 regulation	 of	 IL-1β	 (Zielinski	 et	 al.,	 2012).	 Th17	 immunity	might	 also	mediate	protection	following	intravaginal	HSV-2	challenge	(Anipindi	et	al.,	2016).	The	role	of	Th17	immunity	in	the	reproductive	tract	of	women	is	not	well	defined,	however,	 and	 more	 studies	 are	 needed	 to	 investigate	 the	 protective	 properties	offered	by	these	cells.		
1.4.2 The	role	of	Th17	cells	in	HIV	infection	




(Gosselin	et	al.,	2010).	Studies	 in	HIV	chronically	 infected	adults	have	 found	 that	gastrointestinal	 tract	Th17	 cells	were	depleted	 compared	 to	 those	 found	 in	HIV-uninfected	individuals	(Prendergast	et	al.,	2010).	Since	CCR6	is	a	mucosal	homing	receptor,	one	of	 the	explanations	 for	 the	 increased	susceptibility	of	 these	cells	 to	HIV	 infection	might	be	due	to	 their	migration	to	areas	where	HIV	readily	 infects,	such	 as	 the	 genital	 tract	 (Rodriguez-Garcia	 et	 al.,	 2014;	 Stieh	 et	 al.,	 2016).	 Their	role	 in	 mucosal	 epithelial	 repair	 also	 places	 them	 where	 barrier	 integrity	 is	weakened,	which	are	points	at	which	HIV	can	easily	enter.			
Ex	vivo	experiments	using	mixed	cell	suspensions	from	tissues	taken	from	the	FRT	of	women	 found	 the	highest	number	of	HIV-infected	Th17	cells	 in	 the	ectocervix	compared	 to	 endocervix	 and	 endometrium	 (Rodriguez-Garcia	 et	 al.,	 2014).	Interestingly,	 Th17	 cells	 at	 all	 the	 three	 sites	 expressed	 higher	 levels	 of	 CCR5	compared	 to	 CCR6-	 CD4+	 T	 cells.	 Expression	 of	 CCR5	 together	 with	 mucosal	integrin	α4β7,	which	binds	to	HIV-1	gp120	and	enhances	viral	dissemination,	may	increase	susceptibility	to	HIV	(Sivro	et	al.,	2018).	Th17	cells	were	also	dramatically	depleted	 in	 the	 cervical	 mucosa	 after	 HIV	 infection,	 suggesting	 preferential	infection	(McKinnon	et	al.,	2011;	Masson	et	al.,	2015b).	Given	the	susceptibility	of	Th17	 cells	 to	 HIV	 infection,	 there	 is	 a	 need	 to	 study	 the	 factors	 influencing	 the	characteristics	of	this	CD4+	T	cell	subset,	especially	in	key	risk	groups	like	AGYW.			
1.5 Biological	factors	associated	with	HIV	infection	in	the	FRT	




(HCs),	 genital	 inflammation,	 sexually	 transmitted	 infections	 (STIs),	 and	 bacterial	vaginosis	(BV).	These	will	be	discussed	in	the	subsequent	sections.		
1.5.1 Inflammation	and	immune	activation	




	A	number	of	conditions	and	practices	contribute	to	genital	inflammation,	including	STIs	 (section	 1.5.2)	 and	 BV	 (section	 1.5.3),	 douching,	 cleansing,	 using	 vaginal	drying	 agents	 and	 lubricants	 (Myer	 et	 al.,	 2005;	 Alcaide	 et	 al.,	 2016),	 normal	hormone	cycling	(section	1.6)	and	the	use	of	HCs	(section	1.7;	Jabbour	et	al.,	2009;	Morrison	et	al.,	2014;	Guthrie	et	al.,	2015;	Tasker	et	al.,	2017).		
1.5.2 Sexually	transmitted	infections	
STIs	have	been	linked	with	a	heightened	risk	of	HIV	acquisition	(Steen	et	al.,	2009;	Ward	and	Rönn,	2011).	Recently,	SA	adolescent	girls	were	shown	to	bear	a	higher	burden	of	STIs	compared	to	their	male	counterparts	(Francis	et	al.,	2018).	A	meta-analysis	done	in	SSA	also	reported	a	higher	prevalence	of	STIs	in	AGYW	aged	15-24	years	than	older	women	(Torrone	et	al.,	2018).	SA	and	most	countries	in	SSA	have	adopted	 the	 WHO	 guidelines	 of	 syndromic	 management	 of	 STIs,	 in	 which	 only	symptomatic	 STIs	would	 be	 treated	with	 antibiotics	 (WHO,	 2004).	However,	 the	majority	of	STIs	in	women	in	particular	are	asymptomatic	and	therefore	would	not	be	 treated	 (Barnabas	 et	 al.,	 2017).	 In	 most	 cases	 in	 resource-limited	 African	countries,	 both	 symptomatic	 and	 asymptomatic	 STIs	 remain	 undiagnosed	 and	therefore	 untreated	 (Barnabas	 et	 al.,	 2017;	 Torrone	 et	 al.,	 2018).	 In	 addition	 to	increasing	HIV	acquisition	risk,	untreated	STIs	may	result	in	several	other	adverse	consequences	 including	 pelvic	 inflammatory	 disease	 (PID),	 adverse	 pregnancy	outcomes	and	infertility.			Different	 pathogens	 cause	 STIs,	 including	 various	 bacterial	 (such	 as	 Chlamydia	
trachomatis,	Mycoplasma	genitalium,	 Treponema	pallidum	 [causing	 syphilis]	 and	




trachomatis	 causing	 severe	 damage	 to	 the	 upper	 FRT,	 including	 infertility.	Infection	with	chlamydia	initiates	both	innate	and	adaptive	immune	responses	in	the	genital	tract	(Hafner	et	al.,	2008;	Vasilevsky	et	al.,	2014),	and	CD4+	T	cells	have	been	shown	to	play	a	central	role	in	controlling	infection	through	IFN-γ	secretion	(Nagarajan	et	al.,	2005;	Nelson	et	al.,	2005;	Nogueira	et	al.,	2017).	Chlamydia	has	been	 suggested	 to	 increase	 the	 risk	 of	 acquiring	 HIV-1	 by	 increasing	 pro-inflammatory	cytokines	and	disrupting	genital	epithelial	cells	(Ficarra	et	al.,	2008;	Schust	 et	 al.,	 2012;	 Buckner	 et	 al.,	 2016).	 Moreover,	 chlamydia	 positive	 women	were	 reported	 to	 have	 a	 dramatic	 increase	 in	 the	 number	 of	 CXCR4	 and	 CCR5	chemokine	 receptors	 on	 their	 CD4+	 T	 cells	 in	 the	 endocervix	 compared	 to	chlamydia	negative	women,	suggesting	that	they	may	be	highly	susceptible	to	HIV-1	 infection	 (Schust	 et	 al.,	 2012).	 In	mice,	 it	 has	 been	 shown	 that	 chlamydia	 also	elicits	 Th1	 and	 Th17	 immune	 responses	 that	 may	 promote	 both	 pathogen	clearance	and	genital	tract	damage	(Vicetti	Miguel	et	al.,	2016).	
	
M.	 genitalium	 is	 also	 often	 asymptomatic,	 and	 studies	 have	 found	 that	 these	infections	can	persist	 for	almost	 two	years	 (Jensen,	2006;	Cohen	et	al.,	2007).	M.	
genitalium	has	been	associated	with	PID,	cervicitis	and	other	adverse	reproductive	health	consequences.	In	a	systematic	review	and	meta-analysis,	M.	genitalium	was	associated	with	increased	risk	of	HIV	acquisition,	and	this	association	was	stronger	in	SSA	where	the	burden	of	HIV	is	greatest	(Mavedzenge	and	Weiss,	2009).	Several	studies	 have	 reported	 that	M.	genitalium	 infection	 in	 women	 is	 associated	 with	inflammatory	 responses,	 triggering	 the	 production	 of	 cytokines	 and	 the	recruitment	 of	 activated	HIV	 target	 cells	 (Zhang	 and	Wear,	 2000;	 Starnbach	 and	Roan,	2008;	Wu	et	al.,	2008;	Masson	et	al.,	2014).		




Of	the	protozoal	STIs,	T.	vaginalis	is	the	most	common	non-viral	and	non-bacterial	STI	worldwide	and	recently	 there	has	been	an	alarming	rise	 in	 the	prevalence	of	this	 STI	 in	 adolescents	 (Fichorova	 et	 al.,	 2015).	 T.	 vaginalis	 is	 a	 flagellated	unicellular	 organism,	 which	 adheres	 to	 vaginal	 epithelial	 cells	 and	 causes	disruption	 of	 the	 epithelial	 layer,	 partially	 due	 to	 flagellation	 (Schwebke	 and	Burgess,	 2004;	 Midlej	 and	 Benchimol,	 2010).	 Trichomonas	 has	 also	 been	associated	 with	 increased	 susceptibility	 to	 HIV,	 as	 well	 as	 HSV-2	 (Hirt	 and	Sherrard,	2015).			HSV-2	 is	a	prevalent	viral	STI	 that	accounts	 for	approximately	30%	of	all	STIs	 in	SSA	 (Looker	 et	 al.,	 2015).	 A	 recent	meta-analysis	 reported	HIV	 acquisition	 to	 be	almost	tripled	in	the	presence	of	HSV-2	infection	in	both	women	and	men	(Looker	et	al.,	2017).	In	adolescent	girls	between	the	ages	of	16-18	years,	a	study	in	rural	KwaZulu-Natal	 showed	 a	 prevalence	 of	 10%	 (Karim	 et	 al.,	 2014).	 Following	primary	 infection,	HSV-2	 remains	 latent	 in	 the	 sacral	 ganglia	of	 infected	persons	and	reactivates	periodically,	causing	genital	ulceration	and	viral	shedding	(Croen	et	al.,	1991).	Studies	have	also	shown	that	women	may	shed	HSV-2	in	their	genital	secretions	 without	 any	 clinical	 symptoms	 (Cherpes	 et	 al.,	 2005).	 However,	ulceration	caused	by	HSV-2	has	been	associated	with	increased	activated	CD4+	T	cells,	 providing	more	 target	 cells	 for	HIV	 (Rebbapragada	 et	 al.,	 2007),	 and	 these	CD4+	 T	 cells	 expressing	 CCR5	 persist	 even	 in	 healed	 genital	 lesions	 (Zhu	 et	 al.,	2009).	 The	 high	 burden	 of	 HSV-2	 is	 thought	 to	 have	 contributed	 to	 the	 high	prevalence	of	HIV	in	SSA	(Wald	and	Link,	2002;	Freeman	et	al.,	2006).			
1.5.3 The	vaginal	microbiome	and	bacteria	vaginosis	(BV)	




2007).	Vaginal	Lactobacillus	spp,	metabolize	glycogen	to	produce	lactic	acid	(both	D-	 and	 L-isomers)	 that	 maintain	 the	 lower	 FRT	 pH	 <4.5	 (Huang	 et	 al.,	 2014;	Mirmonsef	et	al.,	2014).	While	the	lower	FRT	is	typically	colonized	by	Lactobacilli	spp.	during	health,	vaginal	hygiene	practices,	sexual	behaviours	and	even	diet	may	cause	disturbances	in	the	VMB	(Myer	et	al.,	2005;	Hutchinson	et	al.,	2007;	Thoma	et	al.,	2011;	Alcaide	et	al.,	2015).			Disturbances	 in	Lactobacilli	colonization	of	 the	vagina	 is	associated	with	a	highly	prevalent,	 recurrent	or	persistent	vaginal	dysbiosis	–	 called	BV	–	which	 typically	results	in	the	vaginal	pH	increasing	to	>4.5	(Ravel	et	al.,	2011;	Gajer	et	al.,	2012).	BV	is	further	characterized	by	an	overgrowth	of	endogenous	bacteria	communities	(thought	 to	 originate	 from	 the	 GI	 tract	 or	 male	 partners)	 and	 a	 relatively	 low	abundance	of	vaginal	Lactobacillus	spp	(Ma	et	al.,	2012).	Lactobacillus	crispatus	has	been	described	to	be	the	most	abundant	bacteria	in	the	healthy	vagina	specifically	in	women	of	European	ancestry	(Ravel	et	al.,	2011).	L.	crispatus	has	been	shown	in	
vitro	 to	 inhibit	 Candida	 albicans,	 and	 protect	 HeLa	 cells	 from	 infection	 by	chlamydia	(Rizzo	et	al.,	2013;	Petrova	et	al.,	2015;	Nardini	et	al.,	2016).			Although	 debate	 on	 the	 classification	 of	 VMB	 during	 health	 and	 BV	 states	 is	ongoing,	Ravel	et	al.	(2011)	initially	suggested	that	these	can	be	divided	into	five	community	 types	 (CTs):	 characterized	 by	 the	 predominant	 bacteria	 spp	 of	 L.	
crispatus	(CT	I),	L.	gasseri	(CT	II),	L.	iners	(CT	III),	L.	jensenii	(CT	IV),	and	a	diverse	VMB	 dominated	 by	 anaerobes	 (CT	 V).	 More	 recently,	 Anahtar	 et	 al.	 (2015)	suggested	 that	 this	 could	 be	 simplified	 into	 four	 CTs;	with	 CT	 I	 dominated	 by	L.	





by	 L.	 crispatus	 (considered	 C2),	 and	 L.	 iners	 (considered	 C3)	 would	 be	 grouped	separately	(Figure	1.4;	Lennard	et	al.,	2017).			Irrespective	of	geographical	location,	women	with	BV	have	bacterial	communities	dominated	by	a	more	diverse	VMB	(composed	of	G.	vaginalis,	Atopobium	vaginae,	
Prevotella	bivia	and	other	facultative	anaerobic	gram-positive	or	negative	bacteria;		Ravel	et	al.,	2011;	Srinivasan	et	al.,	2012;	Anahtar	et	al.,	2015;	Petrova	et	al.,	2015;	Lennard	 et	 al.,	 2017).	 However,	 this	 classification	 of	 BV	 is	 not	 simple,	 as	 some	healthy	women	do	not	have	a	 lactobacilli-dominated	vagina	(Petrova	et	al.,	2017;	Bayigga	et	al.,	2018).				
	
Figure	1.4.	 Composition	of	 the	 vaginal	microbiota	 according	 the	 community	 types	
describe	 in	 young	 SA	 women	 by	 Lennard	 et	 al	 (2017).	 A	 healthy	 vagina	 has	 been	described	as	that	dominated	by	L.	crispatus.	Healthy	African	women	however	mostly	have	






characteristics:	 (i)	vaginal	pH	>4.5,	 (ii)	 the	presence	of	 clue	cells	on	a	 saline	wet	mount,	(iii)	a	homogenous	and	thin	vaginal	discharge,	and	(iv)	a	release	of	a	fishy	amine	odor	after	adding	potassium	hydroxide.	For	a	patient	 to	be	considered	BV	positive	 by	 Amsel	 criteria	 and	 receive	 antibiotic	 treatment,	 three	 of	 these	 four	clinical	characteristics	have	to	be	evident	(Amsel	et	al.,	1983).		BV	increases	HIV-1	risk	significantly	(Low	et	al.,	2011;	Cohen	et	al.,	2012;	Achilles	and	Hillier,	2013).	Women	with	BV	are	at	a	heightened	risk	of	HIV	acquisition,	and	HIV	positive	women	with	BV	are	three	times	more	 likely	to	transmit	 the	virus	to	their	male	partners	(Coleman	et	al.,	2007;	Cohen	et	al.,	2012).	Moreover,	BV	is	also	associated	with	an	up	to	1.9-fold	increased	incidence	of	bacterial	STIs	(Wiesenfeld	et	al.,	2003).	The	mechanism	by	which	BV	increases	HIV	risk	 in	women	has	been	attributed	 to	 several	 factors;	 including	 increased	 concentrations	 of	 pro-inflammatory	mediators,	such	as	IL-1α,	IL-1β	and	TNF-α,	in	BV	positive	compared	to	BV	negative	women	(Masson	et	al.,	2014;	Joag	et	al.,	2018).	The	increase	in	these	pro-inflammatory	 cytokines	 may	 facilitate	 HIV	 infection	 by	 disrupting	 the	epithelial	barrier	(Bruewer	et	al.,	2003),	and	by	activating	nuclear	factor-κB,	which	binds	to	the	HIV	long	terminal	repeat	and	promotes	HIV	replication	(Osborne	et	al.,	1989;	Stroud	et	al.,	2009).			
1.6 Endogenous	female	sex	hormones		




the	ovum	can	be	released	into	the	fallopian	tube.	The	ruptured	follicle	becomes	the	corpus	 luteum,	 which	 produces	 both	 E2	 and	 P4	 needed	 to	 maintain	 optimum	conditions	 for	 fertilization	 and	 implantation	 during	 this	 luteal	 phase.	 In	 the	absence	 of	 pregnancy,	 the	 corpus	 luteum	 shrinks	 and	 levels	 of	 E2	 and	 P4	 start	decreasing.	 P4	 plays	 a	 role	 in	 maintaining	 pregnancy,	 whereby	 increased	 levels	lead	 to	 inhibition	 of	 ovulation	 during	 pregnancy,	 while	 decreased	 levels	 lead	 to	menstruation	and	endometrial	repair	(Challis	et	al.,	2009).		
1.6.1 Effect	of	endogenous	hormones	on	FRT	microenvironment	










the	epithelial	barrier	 in	 the	FRT.	 The	 follicular	phase	 is	 characterized	by	 increases	 in	anti-proteases,	 anti-inflammatory	 cytokines	 and	 an	 intact	 epithelial	 barrier.	 Similarly,	during	 ovulation	 there	 is	 a	 high	 level	 of	 anti-proteases	 in	 addition	 to	 AMPs.	 The	 luteal	phase	has	high	levels	of	pro-inflammatory	cytokines	causing	an	influx	of	highly	activated	CD4+	 T	 cells	 expressing	 CCR6	 and	 CCR5.	 Although	 the	mucus	 layer	 is	 thick	 during	 this	time,	the	epithelial	barrier	integrity	is	weakened.	Figure	drawn	by	Iyaloo	Konstantinus.		
1.7 Hormonal	contraceptives	









































became	available	 in	the	private	health	sector	 in	South	Africa	 in	2013	(Figure	1.7;	Roumen,	2008).	It	is	made	of	the	inert	copolymer	evatane,	and	it	measures	54mm	in	diameter	and	4mm	in	thickness,	that	contains	a	combination	of	ethinylestradiol	(EE)	and	etonogestrel	(ENG)	which	are	equally	dispersed	inside	the	ring	(Mulders	and	Dieben,	2001).	NuvaRing®	slowly	 releases	a	 low	dose	of	progestin	ENG	and	estrogen	EE	over	three	weeks,	which	are	absorbed	through	the	vaginal	epithelium.	On	average,	 it	 is	 estimated	 that	120μg	of	ENG	and	15μg	of	EE	are	 released	daily	from	 the	 ring	 (Timmer	and	Mulders,	 2000;	Oddsson	et	 al.,	 2005).	The	maximum	concentration	 of	 EE	 (approximately	 35pg/ml)	 is	 attained	within	 2-3	 days,	while	the	maximum	concentration	of	ENG	(approximately	1700pg/ml)	is	attained	after	1	week	of	ring	 insertion.	The	manufacturers	recommend	that	 the	 three	continuous	weeks	of	use	be	 followed	by	a	ring	free	week,	during	which	withdrawal	bleeding	normally	 occurs.	 The	 main	 advantages	 of	 NuvaRing	 are	 the	 lower	 doses	 of	contraceptive	hormones	released	and	convenience	of	using	 it	 for	a	whole	month.	The	 daily	 controlled-release	 of	 hormones	 also	 avoids	 fluctuation	 in	 hormone	levels.	NuvaRing	has	also	be	shown	to	produce	superior	cycle	control	compared	to	COCPs	with	the	same	hormone	formulation	(Bjarnadóttir	et	al.,	2002).										
	
	





COCPs	 are	 taken	 orally	 each	 day	 to	 prevent	 pregnancy,	 being	 the	 third	 most	popular	HC	method	globally	(UNDESA,	2015).	Early	COCPs	regimens	consisted	of	a	28-day	pill	pack,	which	included	7	placebo	pills	taken	at	the	end	of	the	21	days	to	initiate	 withdrawal	 bleeding	 (Nappi	 et	 al.,	 2016).	 Other	 regimens	 with	 shorter	hormone	free	days	(2-4	days)	are	now	available	on	the	market,	as	they	have	lighter	and	shorter	withdrawal	bleeds	(Ahrendt	et	al.,	2009;	Mansour	et	al.,	2011).	Of	the	many	COCPs	available	on	the	market,	Nordette®	and	Trisaphil®	birth	control	pills	are	 commonly	 available	 in	 South	 Africa,	 and	 contain	 LNG	 and	 EE.	 Nordette®	COCPs	 contains	 0.15mg	 of	 LNG	 [d(-)-13	 betaethyl-17-alpha-ethinyl-17-beta-hydroxygon-4-en-3-one],	 and	0.03mg	of	EE,	 [19-nor-17α-pregna-1,3,5	 (10)-trien-20-yne-3,17-diol].	 In	 contrast,	 Trisaphil®	 has	 a	 triphasic	 hormonal	 regimen	 of	three	different	drugs:	phase	1	is	comprised	of	6	tablets	each	containing	0.05mg	of	LNG,	and	0.03mg	of	EE;	phase	2	is	comprised	of	5	tablets,	each	containing	0.075mg	LNG	 and	 0.04mg	 EE;	 and	 phase	 3	 is	 comprised	 of	 10	 tablets,	 each	 containing	0.125mg	 LNG	 and	 0.03mg	 EE.	 A	 major	 drawback	 of	 COCPs	 is	 that	 daily	 intake	makes	compliance	more	difficult,	 and	also	 the	occurrence	of	daily	 fluctuations	of	hormonal	plasma	levels.		
1.7.4 Public	health	perspective	on	HCs	and	HIV	acquisition		




Several	 observational	 and	 recent	 meta-analyses	 have	 shown	 that	 DMPA	significantly	 increases	a	woman’s	risk	of	HIV-1	 infection	(Hild-Petito	et	al.,	1998;	Trunova	 et	 al.,	 2006;	 Morrison	 et	 al.,	 2015;	Wall	 et	 al.,	 2015;	 Polis	 et	 al.,	 2016;	Butler	 et	 al.,	 2016).	 In	 contrast,	 there	 is	 still	 no	 convincing	 evidence	on	HIV	 risk	from	 observational	 studies	 on	 NET-EN	 and	 COCPs,	 and	 insufficient	 studies	 on	NuvaRing,	 HC	 patches,	 or	HC	 implants	 (Polis	 et	 al.,	 2016).	 Because	 the	 available	epidemiological	 data	 vary	 in	quality,	 the	WHO	have	 resisted	 changing	 guidelines	on	use	of	the	injectable	DMPA	formulation.	There	is	a	risk	that	taking	DMPA	off	the	market	 may	 be	 more	 harmful	 to	 infant	 and	 maternal	 health,	 as	 women	 may	experience	 unintended	 pregnancies	 as	 a	 consequence.	 To	 improve	 confidence	 in	the	observational	risk	data,	a	randomized	controlled	trial	has	just	been	completed	–	called	the	“Evidence	for	Contraceptive	Options	and	HIV	Outcomes	(ECHO)”	study	-	a	multi-centre,	open-label,	 randomized	clinical	 trial	comparing	HIV	 incidence	 in	women	 using	 DMPA,	 LNG,	 and	 Cu-IUD,	 and	 the	 results	 will	 be	 communicated	during	2019	(http://echo-consortium.com).			
1.8 Biological	mechanisms	by	which	HCs	increase	risk	for	HIV	
infection	





Figure	 1.8.	 Summary	 of	 proposed	mechanisms	 by	 which	 HCs	 contribute	 to	 HIV-1	
transmission.	HCs	alter	immunity,	disrupt	vaginal	structures,	increase	genital	infections,	and	alter	the	VMB.	Figure	drawn	by	Iyaloo	Konstantinus.			
1.8.1 Impact	of	HCs	on	structural	features	of	the	FRT	


















and	 compromise	 the	 integrity	 of	 the	 epithelial	 barrier.	 In	 a	 South	 African	 study,	women	with	clinically	signs	of	a	disrupted	genital	epithelium	and	abnormal	vaginal	discharge	were	at	the	highest	risk	for	HIV	acquisition	(Hazard	ratio:	4.30,	95%	CI:	2.55,	8.22;	Abbai	et	al.,	2016).			HCs	have	been	reported	 to	cause	cervical	ectopy	(Venkatesh	and	Cu-uvin,	2013),	with	 COCPs	 being	 associated	 with	 the	 largest	 areas	 of	 cervical	 ectopy,	 but	 not	DMPA	(Bright	et	al.,	2014).	Ectopy	in	turn	is	associated	with	a	heightened	HIV	risk	(Moss	et	al.,	1991).	Adolescents	are	more	likely	to	have	larger	areas	of	ectopy	due	to	metaplasia,	 which	 can	 occur	 during	 puberty	 (Moscicki	 et	 al.,	 1999).	 It	 is	 also	during	this	time	that	adolescents	seek	HCs.			
1.8.2 Impact	of	HCs	on	immunity	










A	 number	 of	 studies	 have	 identified	 associations	 between	 the	 use	 of	 HCs	 and	acquisition	of	STIs	(other	than	HIV).	COCP	use	has	been	reported	to	increase	risk	for	chlamydia,	and	HPV	infection	(Cottingham	and	Hunter,	1992;	Borgdorff	et	al.,	2015).	 DMPA,	 similarly,	 was	 shown	 to	 increase	 susceptibility	 to	 HSV-2	 and	decrease	 immune	 responses	 to	HSV-2	 in	mice	 (Gillgrass	 et	 al.,	 2003).	 In	women,	DMPA	use	was	found	to	be	at	double	the	risk	of	acquiring	HSV-2	compared	to	those	not	 using	 HCs	 (Grabowski	 et	 al.,	 2015).	 Baeten	 et	 al.	 (2001)	 reported	 that	 both	injectable	 HCs	 and	 COCPs	 were	 associated	 with	 increased	 risk	 of	 chlamydia	infection.	However,	no	association	was	observed	between	DMPA	use	and	risk	 for	syphilis	and	gonorrhoea	infection	(Baeten	et	al.,	2001;	Harris	et	al.,	2009;	Marks	et	al.,	2011;	Noguchi	et	al.,	2014).			
1.8.4 Influence	of	HCs	on	the	VMB	




DMPA	use	has	been	associated	with	decreased	concentrations	of	H2O2-producing	lactobacilli,	 but	 also	 decreased	 concentrations	 of	 G.	 vaginalis	and	 total	 bacterial	load	(Mitchell	et	al.,	2014;	Roxby	et	al.,	2016).	The	hypo-estrogenic	effect	of	DMPA	(and	the	effects	this	lack	of	estrogen	has	on	important	nutrients	needed	to	sustain	protective	 lactobacilli	 in	 the	vagina)	has	been	proposed	 to	be	 the	mechanism	by	which	this	HC	method	alters	the	VMB	(Wessels	et	al.,	2018).			
1.9 Study	aims	and	objectives	
The	 overall	 aim	 of	 this	 dissertation	 is	 to	 investigate	 the	 impact	 of	 several	 HC	methods	on	the	immune	microenvironment	of	the	FRT	of	South	African	adolescent	girls	(15-19	years)	at	risk	for	HIV	acquisition,	in	a	randomized	crossover	study.		



































The	following	genital	tract	samples	were	collected	in	the	following	order:	1. Menstrual	cup	(MC):	Cervicovaginal	secretions	were	collected	by	inserting	a	menstrual	 cup	 (Softcup®)	 for	 30	 minutes.	 These	 were	 used	 to	 analyse	Th17-related	cytokines	by	Luminex	(section	2.3.8	and	2.3.9).	2. STI	 testing:	A	 vulvovaginal	 swab	was	 collected	 for	 STI	 testing	using	 an	 in	house	 validated	 multiplex	 PCR	 assay,	 which	 was	 performed	 at	 the	 STI	Reference	 Laboratory	 at	 the	 NICD,	 Sandringham	 as	 previously	 described	(Lewis	et	al.,	2012;	section	2.3.4).	3. BV	Nugent	scoring:	Posterior	fornix	and	lateral	wall	swabs	were	collected	to	prepare	a	wet	mount	slide	for	BV	Nugent	scoring	by	Gram	staining,	and	for	detection	 of	 yeast	 hyphae	 and	 spores	 (section	 2.3.4).	 Nugent	 scoring	was	performed	 at	 the	 STI	 Reference	 Laboratory	 at	 the	 NICD,	 Sandringham,	Johannesburg.	4. Vaginal	microbiome:	A	lateral	vaginal	wall	swab	was	collected	for	16S	rRNA	and	shotgun	metagenomic	sequencing,	performed	by	Christina	Balle	(Dept	Immunology,	 UCT).	 The	 microbiome	 data	 will	 not	 be	 included	 in	 this	dissertation	as	it	formed	part	of	Christina	Balle’s	PhD	dissertation,	which	is	currently	being	examined.	5. Flow	 cytometry:	 An	 endocervical	 cytobrush	 (Digene®	 Corporation,	 MD,	USA)	 was	 collected	 for	 cervical	 mononuclear	 cells	 (CMCs),	 which	 were	analysed	using	flow	cytometry	(section	2.3.6).		
2.3.3 Blood	specimens	





Cervical	 swabs	were	sent	 to	 the	National	 Institute	of	Communicable	Diseases	 for	screening	 for	 STIs,	 yeast	 (hyphae	 on	 Gram	 stain	 slide)	 and	 BV	 (Nugent	 scoring;	NICD,	 Johannesburg,	 South	 Africa).	 For	 BV	 diagnosis,	 FLOQSwabsÔ	 (Copan	Diagnostics,	 CA,	 USA)	were	 collected	 from	 the	 lateral	 vaginal	wall	 and	 posterior	fornix,	smeared	onto	a	glass	slide	and	Gram	stained	for	Nugent	scoring.	According	to	Nugent	scores,	women	were	categorized	as	being	BV-negative	(Nugent	scores	0–3),	 having	 intermediate	 microbiota	 (Nugent	 scores	 4–6),	 or	 being	 BV-positive	(Nugent	score	7–10).	For	STI	testing,	a	vulvovaginal	swabs	(DryswabsÔ,	Medical	Wire	 and	 Equipment,	 England)	 were	 collected	 and	 screened	 for	 Neisseria	
gonorrhoeae,	 Mycoplasma	 genitalium,	 Chlamydia	 trachomatis	 and	 Trichomonas	
vaginalis	 by	 multiplex	 PCR	 at	 the	 National	 Health	 Laboratory	 Services	 STI	Surveillance	 laboratory	 in	 Sandringham,	 Johannesburg,	 as	 previously	 described	(Lewis	 et	 al.,	 2012).	 For	measurement	 of	 vaginal	 pH,	 swabs	were	 collected	 from	the	 posterior	 fornix	 and	 lateral	 vaginal	 wall	 and	 then	 rolled	 onto	 pH	 indicator	strips	 and	 compared	 with	 colour	 zones	 representing	 different	 pH	 values	 (pH	range:	3.6-8.2;	Düren,	Germany).		
	
2.3.5 	Processing	of	cervical	cytobrushes		




the	cytobrush	30	times	using	a	sterile	Pasteur	pipette.	The	cytobrush	was	removed	and	discarded.	 The	 cell	 suspension	was	 centrifuged	 at	 320g	 for	 10	minutes.	 The	supernatant	was	collected	and	then	stored	at	-80°C	for	other	assays.	The	pelleted	cells	were	dislodged,	 resuspended	 in	100µl	 phosphate	buffered	 saline	 (PBS)	and	immediately	prepared	for	flow	cytometry.		
2.3.6 	Flow	cytometry	










A	summary	of	the	gating	strategy	used	to	identify	T	cell	populations	and	activation	of	these	cells	is	shown	in	Figure	2.1.	A	time	gate	was	set	to	establish	a	stable	flow	stream	and	exclude	any	 inconsistency,	 followed	by	a	singlet	gate	 to	exclude	cells	clumped	together.	A	dump	channel	was	set	to	exclude	CD14	(monocytes),	CD19	(B	cells)	and	dead	cells.	Live	CD3	were	gated	on	to	exclude	other	cells,	and	CD4+	and	CD8+	cells	were	gated	on	from	the	CD3	population.		










































































































































































Cervicovaginal	 secretions	were	 collected	 by	 inserting	 a	 Softcup®	menstrual	 cup	[(MC),	Evofem	Inc,	CA,	USA]	 for	30	minutes.	The	MC	containing	genital	 fluid	was	placed	 into	 a	 labelled	 sterile	 50ml	 polypropylene	 tube	 (Greiner	 Bio	 One,	Frickenhausen,	 Germany),	 transferred	 to	 4°C	 in	 a	 Nalgene	 (Rochester,	 NY,	 USA)	bench-top	cooler	and	transported	to	the	laboratory	for	further	processing	within	4	hours	of	collection.	In	the	laboratory,	the	MC	was	weighed	and	the	volume	of	the	secreted	 fluid	was	calculated	by	subtracting	the	average	weight	of	 the	50ml	tube	containing	an	unused	MC	(Jaumdally	et	al.,	2017).	The	MC	plastic	membranes	were	pushed	 inside	 out	 using	 a	 sterile	 pipette	 tip	 to	 allow	 the	 collected	 secretions	 to	flow	 out	 of	 the	 MCs	 into	 the	 tubes.	 The	 tubes	 were	 centrifuged	 at	 453g	 for	 10	minutes	 at	 4°C	with	 brakes	 off.	 The	MCs	were	 removed	 after	 centrifugation	 and	discarded.	 The	 MC	 secretions	 were	 diluted	 five-fold	 with	 PBS	 according	 to	 the	calculated	 weight	 of	 the	 collected	 secretions,	 and	 stored	 at	 -80°C	 to	 measure	cytokines	using	Luminex	assays.		
2.3.9 Measurement	of	Th17-related	cytokines	by	Luminex	




the	 assay	 were	 reported	 as	 the	 mid-point	 between	 the	 lowest	 concentrations	measured	for	each	cytokine	and	zero.	Overall,	detection	of	IL-4	and	IL-10	was	low,	with	 only	 37%	 and	 42%	 of	 samples	 having	 detectable	 levels,	 respectively;	 see	Appendix	Table	A1.			
2.3.10 	Statistical	analyses	









Characteristic Median (IQR) or %(n/N) 
 N 151 
Age [median years (range)] 17 (15–19) 
Sexual debut [median years (range)] 15 (14-16) 
Multiple partners [% (n/N)] 9.3% (12/128*) 
Vaginal cleansing [% (n/N)] 12.8% (19/148*) 
BMI (kg/m2) [median (range)] 25.0 (21.8 - 28.9) 
Serum hormone conc. [median (range)]  
E2 (pmol/l)  100.0 (74.7 - 141.8) 
S-FSH (U/L)  4.9 (3.6 - 6.0) 
LH (IU/L)  4.2 (2.0 - 6.0) 
Prior contraceptive method [% (n/N)] 
    None  4.8% (7/144*) 
    DMPA  19.4% (28/144*) 
    NET-EN  65.3% (94/144*) 
    COCPs 8.3% (12/144*) 
    Implanon  2.1% (3/144*) 
Genital infections [% (n/N)]                                 
    No STI or BV  19.2% (29/151) 
    N. gonorrhoeae  12.0% (18/151) 
    T. vaginalis 8.6% (13/151) 
    C. trachomatis 33.1% (50/151) 
    M. genitalium 2.7% (4/151) 
    HSV-2 seropositive 27.1% (41/151) 
    Presence of yeast hyphae 14.6% (22/151) 
BV Nugent scoring [% (n/N)] 
    BV negative (Nugent 0-3) 45.7% (69/151)  
    Intermediate (Nugent 4-6) 11.3% (17/151) 
    BV positive (Nugent 7-10) 43.0% (65/151) 
*Missing values for those n ≠ 151 due to data not provided by some participants 
BV, bacterial vaginosis; BMI, body mass index; E2, estradiol; S-FSH, follicle stimulating hormone; 









































































































Figure	 2.3.	 Cervical	 CD4+	 T	 cells	 in	 young	 adolescents.	 (A)	 Proportions	 of	 different	subsets	 of	 CD4+	 T	 cells	 defined	 by	 CCR6	 and	 CCR10	 chemokine	 receptors.	 Th17	 cells	(CCR6+CCR10-)	are	represented	by	the	blue	dots,	CCR6-CCR10+	CD4+	T	cells	are	shown	in	clear	squares,	CCR6+CCR10+	CD4+	T	cells	are	shown	in	clear	triangles,	and	CCR6-CCR10-	CD4+	T	 cells	 are	 shown	 in	black	 inverted	 triangles.	 (B)	Frequencies	of	CD38+	and	HLA-DR+	Th17	cells	 (CCR6+CCR10-;	blue	bars)	 and	Th1/2-like	T	 cells	 (CCR6-CCR10-;	black).	(C)	Expression	of	CCR5	alone	and	in	combination	with	CD38	and/or	HLA-DR	by	Th17	cells	(CCR6+CCR10-;	blue	bars)	and	Th1/2-like	T	cells	(CCR6-CCR10-;	black).	Mann-Whitney	U	tests	 were	 applied	 to	 compare	 the	 markers	 between	 the	 groups,	 and	 p≤0.05	 were	considered	significant.		

































































































Figure	 2.4.	 Abundance	 of	 Th17-related	 cytokines	 in	 the	 lower	 reproductive	 tract	
(LRT)	of	adolescent	girls.	Cytokines	were	grouped	into	three	groups	according	to	their	primary	Th17-related	functions;	 including	those	produced	by	Th17	cells	(IL-17A,	IL-17F,	IL-21,	IL-22),	those	involved	in	Th17	differentiation	(IL-6,	IL-1β,	IL-23,	IL-33,	TNF-α),	and	those	 involved	 in	 regulating	 Th17	 cells	 (IL-4,	 IL-10,	 IL-25,	 IL-31,	 IFN-γ,	 sCD40L).	 The	median	(middle	lines)	and	IQR	(error	bars)	are	plotted	on	the	graph.			

























Figure	 2.5.	 Correlation	 between	 Th17-related	 cytokines	 in	 genital	 secretions	 of	
adolescent	girls.	 Cytokines	were	 grouped	 into	 three	 groups	 according	 to	 their	primary	Th17-related	functions;	including	those	produced	by	Th17	cells	(IL-17A,	IL-17F,	IL-21,	IL-22),	 those	 involved	 in	 Th17	 differentiation	 (IL-6,	 IL-1β,	 IL-23,	 IL-33,	 TNF-α),	 and	 those	involved	in	regulating	Th17	cells	(IL-4,	IL-10,	IL-25,	IL-31,	IFN-γ,	sCD40L).	Only	significant	correlation	 coefficients	 (Rho	 scores)	 are	 displayed	 in	 blue	 (representing	 positive	correlations).	
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2.4.4 Relationship	 between	 Th17	 cell	 frequencies	 and	 Th17-
related	cytokines		
The	relationship	between	Th17	cells	and	Th17-related	cytokines	was	investigated.	Frequencies	of	cervical	Th17	cells	in	cytobrushes	did	not	appear	to	correlate	with	concentrations	 of	 the	 Th17-related	 cytokines	 (data	 not	 shown).	 However,	 the	extent	 of	 Th17	 activation	 (CD38+)	 tended	 to	 correlate	 positively	 with	 genital	concentrations	 of	 IL-17A	 (r=0.22,	 p=0.01),	 IL-17F	 (r=0.17,	 p=0.05),	 IL-6	 (r=0.21,	p=0.02),	 IL-10	 (r=0.25,	 p=0.004),	 and	 sCD40L	 (r=0.19,	 p=0.04;	 Figure	 2.6),	although	 none	 of	 these	 associations	 remained	 significant	 after	 adjusting	 for	multiple	 comparisons.	 Interestingly,	 there	 was	 a	 weak	 negative	 correlation	between	the	frequency	of	Th17	cells	expressing	CCR5	and	IL-17A	(p=0.02,	r=-0.20)	(data	not	shown).		
	
Figure	2.6.	Correlation	between	the	frequencies	of	activated	(CD38+)	Th17	cells	and	











































































The	 relationship	 between	 endogenous	 hormone	 levels	 and	 cervical	 Th17	 cell	frequencies	 and	 state	 of	 activation	 was	 next	 investigated.	 While	 FSH	 did	 not	appear	 to	 change	 activation	 or	 frequency	 of	 cervical	 Th17	 cells,	 E2	 correlated	negatively	with	 frequencies	 of	 activated	 Th17	 cells	 expressing	HLA-DR	 (r=-0.23,	p=0.01;	Table	2.3)	and	those	co-expressing	CD38/HLA-DR	(r=-0.22,	p=0.01).	There	were	also	weak	negative	correlations	between	LH	and	Th17	cells	expressing	CD38	(r=-0.22,	p=0.01),	CD38/HLA-DR	(r=-0.20,	p=0.02),	CCR5/CD38	(r=-0.19,	p=0.03),	CCR5/HLA-DR	 (r=-0.19,	 p=0.04)	 and	CCR5/CD38/HLA-DR	 (r=-0.19,	 p=0.03).	The	relationship	 between	 Th17-related	 cytokines	 and	 endogenous	 serum	 hormones	was	also	investigated,	however	there	were	no	statistically	significant	correlations	(data	not	shown).			
Table	2.3	Relationship	between	endogenous	hormone	concentrations	and	cervical	Th17	cell	activation	
		
		 E2	 FSH	 LH	




2.4.6 Impact	 of	 yeast	 infection	 on	 cervical	 Th17	 cells	 and	
cytokines		





Figure	2.7.	 Impact	of	yeast	 infection	on	 frequency	and	activation	status	of	cervical	




























































Figure	 2.8.	 Impact	 of	 yeast	 infection	 on	 genital	 tract	 Th17-related	 cytokine	
concentrations.	Adolescents	without	yeast	infections	are	shown	as	clear	bars,	while	those	with	 a	 yeast	 infection	 are	 shown	 as	 green	 bars.	Mann-Whitney	 U	 tests	 were	 used	 to	compare	the	groups,	and	p≤0.05	were	considered	significant.			
2.4.7 Impact	of	STIs	on	Th17	cells	and	cytokines	







































































Figure	 2.9.	 Impact	 of	 STIs	 (including	 chlamydia,	 gonorrhoeae,	 mycoplasma	 and	





























































line),	 IQR	 (box)	and	range	 (whiskers).	Mann-Whitney	U-tests	were	used	 to	compare	 the	groups,	and	P≤0.05	were	considered	significant.			Research	from	our	group	and	others	have	shown	that	certain	STIs	are	associated	with	 the	 induction	 of	 several	 cytokines,	 including	 IL-1β	 and	 IL-17	 which	 were	measured	in	this	study	(Crowley-Nowick	et	al.,	2000;	Mlisana	et	al.,	2010;	Masson	et	al.,	2014;	Deesa	et	al.,	2015;	Masson	et	al.,	2015b).	In	this	adolescent	cohort,	IL-17A	(p=0.001)	and	IL-1β	(p=0.02)	were	significantly	elevated	in	adolescents	who	had	 an	 STI	 compared	 to	 those	 with	 no	 STI	 (Figure	 2.10).	 IL-1β	 remained	significant,	after	adjusting	for	multiple	comparisons.			
Figure	2.10.	 Impact	of	STIs	on	genital	concentrations	of	Th17-related	cytokines,	 in	






































































Since	chlamydia	infection	was	highly	prevalent	in	this	cohort	(33%,	Table	2.2),	its	effect	 alone	 on	 cervical	 Th17	 cells	 and	 Th17-related	 cytokines	 was	 also	investigated.	For	this	analysis,	13	adolescents	with	asymptomatic	chlamydia	only	(BV+C-)	 were	 compared	 to	 22	 adolescents	 without	 an	 STI	 or	 BV	 (BV-C-).	Chlamydia	did	not	alter	the	frequencies	and	activation	status	of	Th17	cells	(Figure	2.11A).	 On	 the	 contrary,	 IL-17A	 was	 significantly	 elevated	 in	 adolescents	 with	chlamydia	compared	to	those	without	(p=0.004,	Figure	2.11B).			
	
Figure	2.11.	Impact	of	asymptomatic	chlamydia	on	Th17	cell	frequencies,	activation	
status	 and	 concentrations	 of	 Th17-related	 cytokines,	 in	 adolescents	 with	 (black	
box)	 and	 without	 chlamydia	 (purple	 boxes).	 (A)	 Th17	 frequencies	 (left	 panel)	 and	expression	 of	 CCR5,	 CD38	 and	 HLA-DR	 on	 Th17	 cells	 (right	 panel).	 Concentrations	 of	Th17-related	cytokines	in	adolescents	with	and	without	chlamydia.	Box	and	whisker	plots	show	 the	median	 (middle	 line),	 IQR	 (box)	 and	 range	 (whiskers).	Mann-Whitney	U-tests	were	used	to	compare	the	groups,	and	P≤0.05	were	considered	significant.	**p<0.01.	

























































Figure	 2.12.	 Effect	 of	 previous	 contraceptive	 use	 on	 cervical	 Th17	 cell	 activation	
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3.1	Abstract	BV	is	a	common	vaginal	dysbiosis	among	reproductive-aged	women,	caused	by	changes	 in	 vaginal	 microbial	 communities,	 which	 results	 in	 inflammatory	changes	 in	 the	 lower	 FRT.	 Th17	 cells	 are	 known	 to	 be	 important	 for	 defense	against	 bacterial	 infections,	 although	 their	 interaction	 with	 the	 vaginal	microbiota	and	BV	is	not	yet	understood.	Adolescence	is	a	time	of	increased	risk	for	BV	and	Th17	cells	are	abundant	in	the	genital	tracts	of	these	young	women.	The	 aim	 of	 this	 study	was	 to	 evaluate	whether	 BV	 and	 the	 vaginal	microbiota	were	 associated	 with	 changes	 in	 cervicovaginal	 Th17	 cell	 populations	 and	activation	status	 in	AGYW,	as	well	as	with	the	genital	 tract	cytokines	related	to	these	cells.	For	this	study,	BV	was	characterized	by	Nugent	score	(Nugent	7-10	were	 considered	 BV+),	 vaginal	 pH	 was	 measured	 using	 Macherey-Nagel	 pH	strips	 (pH>4.5	 considered	 high),	 and	 16S	 rRNA	 gene	 sequencing	 of	 cervical	swabs	was	 used	 to	 define	 community	 types	 using	 unsupervised	 clustering:	 C1	being	more	 diverse;	 C2	 predominantly	made	 of	Lactobacillus	crispatus;	 and	 C3	predominantly	 made	 up	 of	 Lactobacillus	 iners.	 While	 frequencies	 and	 the	activation	status	of	CCR6+CCR10-	Th17	cells	were	similar	in	BV+	and	BV-	AGYW	(by	 Nugent	 scoring)	 and	 by	 vaginal	 community	 types	 (C1,	 C2	 and	 C3),	 Th17-related	 cytokines	 were	 significantly	 elevated	 in	 BV+	 compared	 to	 BV-	adolescents,	and	in	C1	versus	C2	and	C3	adolescents.	These	findings	suggest	that	microbial	changes	in	the	lower	FRT	of	adolescents	and	BV-associated	changes	do	influence	the	profile	of	Th17-related	cytokines	although	not	Th17	cells.								
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3.2 Introduction	
BV	is	a	highly	prevalent,	recurrent	and	complex	vaginal	dysbiosis	characterized	by	 a	 shift	 in	 the	 vaginal	microbiota	 from	 one	 dominated	 by	 Lactobacillus	 spp.	(including	L.	crispatus,	L.	jensenii,	L.	gasseri,	L.	johnsonii,	and	L.	mucosae)	to	more	diverse	 non-Lactobacillus	 anaerobic	 bacterial	 communities	 dominated	 by	various	species,	including	Prevotella,	Gardnerella,	Atopobium,	and	Sneathia	(Vitali	et	 al.,	 2007;	 Brotman	 et	 al.,	 2010;	 Xia	 et	 al.,	 2016).	 A	 recent	 review	 has	highlighted	 some	 of	 the	 challenges	 that	 the	 international	 scientific	 community	has	faced	in	developing	a	universally	relevant	definition	for	BV	(McKinnon	et	al.,	2019).	McKinnon	et	al.	 (2019)	summarize	some	of	 the	major	reasons	 for	 these	challenges	 being	 that	 “normal”	 bacterial	 profiles	may	 differ	markedly	 between	women,	particularly	women	of	different	ethnicities	(Ravel	et	al.,	2011);	that	the	methodologies	 for	 diagnosing	 BV	 have	 differed	 quite	 widely	 between	 studies;	and	 there	 is	 still	 no	 consensus	 on	 what	 constitutes	 a	 “pathogenic”	 versus	“pathobiont”	 bacterial	 community	 with	 regards	 to	 BV.	 Currently,	 BV	 may	 be	defined	clinically	as	symptomatic	BV	(Klebanoff	et	al.,	2004),	by	high	vaginal	pH	levels	(pH>4.5),	as	“Amsel-BV”	(Amsel	et	al.,	1983),	“Nugent-BV”	(Nugent	et	al.,	1991)	or	“molecular-BV”	(McKinnon	et	al.,	2019),	each	of	which	depends	on	the	method	used	for	diagnosis.			Symptomatic	 BV	 is	 non-specifically	 diagnosed	 if	 women	 present	 with	 vaginal	discharge,	 a	 fishy	 odor	 and	 vaginal	 itching	 or	 burning	 (Amsel	 et	 al.,	 1983).	However,	most	women	with	BV	are	 asymptomatic	 (Mlisana	et	 al.,	 2011).	BV	 is	often	 diagnosed	 in	 the	 clinical	 setting	 using	 Amsel’s	 criteria	 according	 to	 the	release	of	a	fishy	amine	odor	(on	addition	of	potassium	hydroxide),	presence	of	squamous	cells	coated	with	bacteria	(known	as	clue	cells),	and	high	vaginal	pH	levels	(Amsel	et	al.,	1983;	White	et	al.,	2011;	Nelson	et	al.,	2015).	The	sensitivity	and	 specificity	 of	 Amsel’s	 criteria	 have	 ranged	 from	 37%	 to	 70%	 and	 94%	 to	99%,	 respectively,	 compared	 to	 Nugent	 scoring	 (Coleman	 and	 Gaydos,	 2018).	The	current	international	gold	standard	for	diagnosing	BV	is	the	Nugent	scoring	system	 (Nugent,	 1991).	 However,	 this	 method	 is	 not	 used	 frequently	 in	 the	clinical	 setting	 as	 experienced	 laboratory	 staff	 and	 relatively	 specialized	
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equipment	(microscopes	and	gram	stains)	are	needed.	“Molecular-BV”	describes	dysbiosis	identified	using	any	molecular	technique.	Due	to	the	complexity	of	BV,	bacterial	 community	 types	 (CT)	have	become	useful	 for	 the	characterization	of	vaginal	dysbiosis	(Ravel	et	al.,	2011;	Ma	et	al.,	2012).	Vaginal	CTs	characterizes	the	 microbiota	 based	 on	 the	 dominant	 microbial	 species,	 although	 several	groups	 have	 suggested	 different	 classifications	 within	 each	 CT:	 Ravel	 et	 al.	(2011)	 first	 recommended	 five	 CTs	 in	 a	 large	 study	 of	 more	 than	 300	asymptomatic	North	American	women	(including	African,	Caucasian,	Asian	and	Hispanic	American	women);	Anahtar	et	al.	(2015)	subsequently	suggested	that	a	four	 CT	 system	 was	 best	 to	 describe	 vaginal	 bacterial	 communities	 in	 146	asymptomatic	 South	 African	 women	 aged	 18-23	 years;	 and	 authors	 from	 our	group	later	argued	for	a	three	CT	system	with	Cluster	1	(C1)	being	most	diverse,	Cluster	 2	 (C2)	 being	 dominated	 by	 L.	 crispatus,	 and	 Cluster	 3	 (C3)	 being	dominated	by	L.	iners	(Lennard	et	al.,	2017).			Vaginal	 microbiome	 studies	 have	 found	 a	 strong	 correlation	 between	 high-diversity	microbial	 communities	 and	BV	diagnosed	 by	Nugent	 scoring	 (Van	de	Wijgert	 et	 al.,	 2014).	 Despite	 differences	 in	 how	 the	 vaginal	 bacterial	communities	 in	health	and	disease	should	be	clustered,	all	 studies	have	agreed	that	L.	crispatus	and	L.	iners	tend	to	be	the	most	prevalent	vaginal	lactobacilli	in	healthy	women	 (Ravel	 et	 al.,	 2011;	Anahtar	 et	 al.,	 2015;	Gosmann	et	 al.,	 2017;	Lennard	 et	 al.,	 2017;	McClelland	 et	 al,	 2018),	 although	molecular	 studies	 have	shown	 L.	 crispatus	 to	 be	 associated	 with	 better	 health	 outcomes	 than	 L.	 iners	(Ravel	et	al.,	2011;	Gosmann	et	al.,	2017).			Nugent-BV	 has	 been	 associated	with	 a	 1.5–3.0-fold	 increased	 risk	 of	 acquiring	STIs,	 including	HIV	(McClelland	et	al.,	2018;	Low	et	al.,	2011),	HPV	(Gillet	et	al.,	2011),	C.	trachomatis	 and	N.	gonorrhoeae	 (Brotman	et	 al.,	 2010;	Bautista	 et	 al.,	2017),	as	well	as	a	3-fold	increased	risk	of	HIV-1	transmission	to	a	male	partner	(Cohen	et	al.,	2012;	Klatt	et	al.,	2017).	This	is	particularly	concerning	in	young	SA	women,	as	HIV	is	exceptionally	prevalent	in	this	group	and	recent	data	estimates	the	prevalence	of	BV	 in	 these	women	to	be	around	42%	(Kharsany	and	Karim,	2016;	Torrone	et	al.,	2018).	The	association	between	BV	and	HIV	acquisition	 is	
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As	described	in	Chapter	2,	a	total	of	151	HIV-negative	adolescent	girls	screened	at	 baseline	 were	 included	 in	 this	 cross-sectional	 analysis	 of	 the	 relationship	between	 BV	 and	 Th17	 cell	 frequencies	 (and/or	 their	 activation	 status;	 see	Chapter	 2,	 section	 2.3.1).	 Demographic,	 behavioral	 and	 clinical	 data	 was	collected	 as	 described	 in	 Chapter	 2	 and	 the	 same	AGYW	were	 included	 in	 this	analysis.		
 BV	diagnosis	
A	lateral	vaginal	wall/posterior	fornix	swab	was	collected	from	each	adolescent	for	Gram	staining	and	Nugent	scoring	(for	Nugent	scoring),	which	was	scored	at	the	 National	 Institute	 of	 Communicable	 Diseases	 (NICD,	 Sandringham,	Johannesburg).	 According	 to	Nugent	 score	 criteria,	 AGYW	were	 categorized	 as	being	BV	negative	(Nugent	scores	0–3),	having	intermediate	microbiota	(Nugent	scores	 4–6),	 or	 being	 BV	 positive	 (Nugent	 scores	 7–10).	 Vaginal	 pH	 was	measured	using	colour-fixed	indicator	strips	(Macherey-Nagel,	Duren,	Germany),	and	normal	vaginal	pH	was	considered	pH≤4.5	(Money	et	al.,	2005).	
	
 	Processing	of	cervical	cytobrushes	and	flow	cytometry	
Cervical	 cytobrushes	 were	 collected	 as	 described	 in	 Chapter	 2	 (section	 2.3.5),	and	processed	within	4	hours.	The	 freshly	 collected	cervical	 cells	were	stained	using	 a	 flow	 cytometry	 panel	 as	 described	 in	 Chapter	 2	 (section	 2.3.6),	 which	was	optimized	for	this	study.		
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 Measurement	of	Th17-related	cytokines	
The	concentrations	of	Th17-related	cytokines	(IL-17A,	IL-17F,	IL-21,	IL-22,	IL-6,	IL-1β,	 IL-23,	 IL-33,	 TNF-α,	 IL-4,	 IL-10,	 IL-25,	 IL-31,	 IFN-γ	 and	 sCD40L)	 were	measured	by	Luminex,	as	described	in	Chapter	2	(section	2.3.9).		
 Vaginal	 16S	 rRNA	 gene	 amplification	 and	 Illumina	miSeq	
sequencing		
Vaginal	lateral	wall	swabs	were	collected	for	microbiome	analysis	by	16S	rRNA	amplicon	 sequencing,	 by	 Christina	 Balle	 as	 part	 of	 the	 larger	 uChOOSE	 study	(Christina	 Balle	 PhD	 thesis),	 and	 the	 method	 had	 been	 described	 elsewhere	(Lennard	 et	 al.,	 2017).	 Briefly,	 available	 swabs	 from	 150	 participants	 were	thawed	 and	 treated	 with	 an	 enzyme	 cocktail	 consisting	 of	 mutanolysin	(25kU/ml,	 Sigma	 Aldrich,	 Modderfontein,	 SA),	 lysozyme	 (450kU/ml,	 Sigma	Aldrich),	 and	 lysostaphin	 (4kU/ml,	 Sigma	 Aldrich)	 for	 1	 hour	 at	 37°C.	 The	microbial	DNA	was	extracted	using	Quick-DNATM	Fungal/Bacterial	Miniprep	kits	(Zymo	Research)	and	prepared	 for	sequencing.	The	V4	hypervariable	region	of	the	 bacterial	 16S	 rRNA	 genes	 was	 amplified	 by	 PCR	 using	 modified	 universal	primers	 (Pearce	 et	 al.,	 2014;	 Lennard	 et	 al.,	 2017).	 Samples	with	 ≥5000	 reads	were	selected	 for	downstream	analyses.	The	operational	 taxonomic	unit	 (OTU)	table	was	normalized	and	filtered	such	that	each	OTU	had	at	least	10	counts	in	at	least	20%	of	samples	or	a	relative	abundance	of	at	 least	0.001%	(as	previously	described;	Lennard	et	al.,	2017).		
 Statistical	analyses	
Baseline	 characteristics	were	 summarized	 using	 descriptive	measures,	 such	 as	median,	 frequencies	 and	 IQR.	 For	 categorical	 variables,	 the	 Fisher’s	 Exact	 test	was	 used	 to	 compare	 groups.	 Non-parametric	 Mann-Whitney	 U	 test	 and	Wilcoxon	 Signed	 Rank	 test	 were	 used	 for	 unmatched	 and	 paired	 samples	respectively.	For	comparison	between	more	than	two	groups,	the	Kruskal-Wallis	one-way	analysis	of	variance	was	used.	Correlations	were	performed	using	 the	
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Spearman	 Rank	 test.	 Multivariate	 logistic	 regression	 was	 used	 to	 assess	associations	 between	 BV	 and	 log10-transformed	 cytokine	 concentrations	 after	adjusting	 for	 possible	 confounders.	 Microbiota	 community	 clusters	 were	established	 by	 Fuzzy	 clustering	 using	 the	 R	 package	 ‘cluster’	 (Maechler	 et	 al.,	2017)	with	optimal	k,	a	membership	exponent	of	1.25	and	weighted	UniFrac	as	the	dissimilarity	measure.	Statistical	analysis	was	performed	using	Prism	version	6.0	(GraphPad	Software,	CA,	USA),	R	Studio	and	STATA™	version	12	(StataCorp,	TX,	USA).	 A	 p-value	 of	 ≤0.05	was	 considered	 to	 be	 statistically	 significant.	 The	Benjamini-Hochberg	 method	 was	 used	 to	 adjust	 for	 multiple	 comparisons	(Benjamini	and	Hochberg,	1995).																					
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3.4 Results	
Of	the	151	adolescents	screened	for	the	uCHOOSE	study	(Table	2.2,	Chapter	2),	46%	(69/151)	were	BV	negative	(Nugent	0-3),	11%	(17/151)	had	intermediate	vaginal	microbiota	(Nugent	4-7),	and	43%	(65/151)	were	BV	positive	(Nugent	7-10;	 Table	 3.1).	 Adolescents	 with	 BV	 (Nugent	 scores	 7-10)	 did	 not	 differ	 from	those	without	BV	(Nugent	scores	0-3)	 in	serum	hormone	 levels	of	FSH	and	LH,	although	 E2	 serum	 levels	 tended	 to	 be	 higher	 in	 those	 with	 BV	 (p=0.03)	 or	intermediate	Nugent	 scores	 (p=0.07).	Behavioural	 characteristics	 and	previous	contraception	 use	were	 similar	 between	 the	 groups	 (Table	 3.1).	 Prevalence	 of	STIs	 was	 high	 overall	 (Table	 2.2,	 Chapter	 2),	 but	 did	 not	 differ	 significantly	according	 to	BV	 status	 (Table	3.1).	However,	 the	prevalence	of	 evident	vaginal	yeast	 infections	 was	 significantly	 higher	 in	 BV-	 adolescents	 than	 BV+	 or	intermediate	 AGYW	 (p=0.02),	 while	 reported	 condom	 use	 was	 higher	 in	 BV-	versus	BV+	or	 intermediate	groups	(p=0.03).	As	has	previously	been	described	(Money	et	al.,	2005;	Hemalatha	et	al.,	2013),	vaginal	pH	was	significantly	higher	in	BV+	compared	to	BV-	adolescents	(pH5.0	[4.7	-	5.3]	versus	pH4.7	[4.4	-	5.0],	respectively,	p<0.0001),	and	those	with	intermediate	microbiota	had	pHs	similar	to	BV+	adolescents	(pH=5.3	[4.8	-	5.6]).				
Table	3.1	Participant	characteristics	according	to	Nugent-BV	status	
	 BV	negative	n=69	 Intermediate	n=17	 BV	positive	n=65	 		
n/N	(%),	Median	(IQR)			 	 	 	 p-value	
Median	age		 17	(16	-	18)	 17	(16	-	19)	 17	(16	-	18)	 0.355	
BMI	(kg/m2)	 25.1	(22.2	-	28.6)	 23.9	(21.4	-	25.3)	 25.8	(21.7	-	30.4)	 0.164	
Serum	hormone	levels	 	 	 	 				E2	(pmol/l)	 93.0	(74.0	-	137.5)	87.0	(57.5	-	129.5)	 107.5	(82.3	-	157.8)	 0.053				S-FSH	(U/L)	 5.0	(3.3	-	6.0)	 5.3	(2.9	-	5.9)	 4.8	(3.6	-	6.1)	 0.973				LH	(IU/L)	 4.0	(2.0	-	5.1)	 4.8	(2.3	-	6.5)	 4.9	(2.0	-	6.7)	 0.111	
Vaginal	pH	 4.7	(4.4	-	5.0)	 5.3	(4.8	-	5.6)	 5.0	(4.7	-	5.3)	 <0.0001	
Genital	infections	 	 	 	 				No	STI	 29/69	(42.0%)	 10/17	(58.8%)	 26/65	(40.0%)	 0.367	




To	evaluate	the	vaginal	microbial	composition	in	AGYW	at	baseline,	the	variable	region	4	(V4)	of	the	bacterial	16S	rRNA	gene	was	sequenced	to	assess	bacterial	relative	abundance	(Anahtar	et	al.,	2015).	Others	from	our	group	have	previously	reported	 that	 observed	 bacterial	 communities	 in	 vaginal	 samples	 from	adolescents	in	the	same	community	clustered	into	three	distinct	CTs	(C1,	C2,	C3)	by	Fuzzy	clustering,	with	weighted	UniFrac	distances	(Lennard	et	al.,	2017).	This	characterization	 of	 vaginal	 communities	was	 adopted	 in	 this	 chapter,	whereby	C1	 represents	 a	 more	 diverse	 microbiota	 with	 low	 Lactobacillus	 abundance,	while	 C2	 and	 C3	 were	 made	 up	 of	 predominantly	 L.	 crispatus	 and	 L.	 iners,	respectively	(Figure	3.1B).	This	analysis	was	conducted	by	Christina	Balle	as	part	of	 her	 PhD	 (submitted).	 Of	 the	 151	 baseline	 samples	 collected,	 141/151	 (BV	negative	 n=64,	 intermediate	 n=14,	 BV	 positive	 n=63)	 had	 sequence	 of	 high	enough	quality	to	analyze	(Balle,	Jaspan	et	al.,	personal	communication).		At	baseline,	52%	(73/141)	of	the	participants	had	a	non-Lactobacillus	dominated	microbiota,	while	 48%	 (68/141)	 had	 a	Lactobacillus-dominated	microbiota.	 Of	
			T.	vaginalis	 5/69	(7.2%)	 4/17	(23.5%)	 5/65	(7.7%)	 0.165	
			C.	trachomatis	 22/69	(31.9%)	 5/17	(29.4%)	 23/65	(35.3%)	 0.999	
			M.	genitalium	 2/69	(2.9%)	 0/17	(0%)	 2/65	(3.1%)	 0.601				HSV-2	serology	 16/69	(23.2%)	 2/17	(11.8%)	 19/65	(29.2%)	 0.440				Presence	of	yeast	hyphae	 16/69	(23.2%)	 2/17	(11.8%)	 5/65	(7.7%)	 0.020	
Behavioural	
characteristics	 	 	 	 				Age	of	sexual	debut	 15	(14	-	16)	 15	(14	-	16)	 15	(14	-	16)	 0.938				Condom	use	always	 43/61	(70.5%)	 9/12	(76.9%)	 26/54	(47.2%)	 0.030				Ever	washed	vagina	 3/69	(4.3%)	 2/18	(11.1%)	 8/65	(12.3%)	 0.217	
Previous	contraceptive	
use	 	 	 	 				None	 3/69	(4.3%)	 1/17	(5.8%)	 3/61	(4.9%)	 0.981				DMPA	 13/69	(18.8%)	 2/17	(11.7%)	 13/61	(21.3%)	 0.608				NET-EN	 45/69	(65.2%)	 12/17	(70.6%)	 37/61	(60.6%)	 0.531				COCP	 5/69	(7.2%)	 1/17	(5.8%)	 6/61	(9.8%)	 0.799				Implanon	 0/69	(0%)	 1/17	(5.8%)	 2/61	(3.2%)	 0.234	BV,	 bacterial	 vaginosis;	 BMI,	 body	 mass	 index;	 E2,	 estradiol;	 S-FSH,	 follicle	 stimulating	 hormone;	 LH,	luitenizing	hormone	
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those	with	a	Lactobacillus-dominant	microbiota,	21%	(30/141)	had	primarily	L.	
crispatus	 and	 27%	 had	 L.	 iners	(38/141).	 When	 these	 clusters	 were	 stratified	according	to	Nugent	criteria	(Figure	3.1A),	97%	of	BV+	adolescents	grouped	into	the	C1	CT	(61/63),	with	the	most	abundant	bacterial	species	being	G.	vaginalis,	
BVAB1,	Megasphaera	spp.,	L.	iners	and	Prevotella	spp.	Of	those	with	intermediate	Nugent	 scores,	 71%	 were	 classified	 into	 C1	 (10/14).	 Of	 those	 who	 were	considered	BV	 negative,	 44%	had	L.	crispatus-dominant	 CTs	 (28/64)	 and	 53%	had	L.	iners-dominant	CTs	(34/64).				
	








































		 	BV	negative	 Intermediate	 BV	positive	 	
																															n/N	(%)	
Community	types	 	 	 	 				C1	 2/64	(3.1%)	 10/14	(71.4%)	 61/63(96.8%)	 <0.0001				C2	 28/64(43.8%)	 2/14	(14.3%)	 0/63	(0%)	 <0.0001				C3	 34/64	(53.1%)	 2/14	(14.3%)	 2/63	(3.2%)	 <0.0001	
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the	 left	 of	 the	 figure	 shows	 the	 relatedness	 of	 different	 bacterial	 taxa.	 Figure	 3.1B	provided	by	Christina	Balle.			
3.4.2 Relationship	between	BV	status	and	Th17	cell	frequencies	
Since	 several	 studies	 have	 shown	 that	 Th17	 cells	 are	 important	 in	 protection	against	bacterial	and	fungal	pathogens	(Pietrella	et	al.,	2011;	Cooper,	2014),	the	relationship	 between	 BV	 status	 and	 cervical	 Th17	 cell	 frequencies	 and/or	activation	status	was	assessed.	Both	the	median	frequencies	of	Th17	cells,	their	relative	 counts,	 and	 the	proportion	expressing	CCR5	or	 activation	markers	did	not	differ	by	BV	status	(Figure	3.2),	irrespective	of	whether	STIs	were	excluded	from	 this	 analysis	 (data	 not	 shown).	 In	 addition,	 no	 significant	 differences	according	to	BV	status	in	overall	CD4+	T	cell	frequencies	or	activation	status	was	observed	(data	not	shown).			
Figure	 3.2.	 Proportion	 and	 phenotype	 of	 Th17	 cells	 stratified	 according	 to	 BV	





































































































3.4.3 Relationship	 between	 Th17	 cell	 frequencies,	 activation	
status	and	vaginal	community	types		
BV-associated	 microbial	 diversity	 in	 the	 vagina	 has	 been	 reported	 to	 be	associated	 with	 increased	 activated	 CD4+	 T	 cell	 frequencies	 in	 some	 cohorts	(Gosmann	 et	 al.,	 2017),	 but	 not	 others	 (Lennard	 et	 al.,	 2017).	 Th17	 cell	frequencies	and	activation	were	thus	compared	between	AGYW	according	to	CTs	to	 determine	 whether	 vaginal	 CTs	 in	 adolescents	 influence	 mucosal	 T	 cell	frequencies	or	function.	The	frequencies	and	counts	of	Th17	cells	were	found	to	be	evenly	distributed	across	the	three	CTs	(Figure	3.3).	Similarly,	expression	of	CCR5,	CD38	and	HLA-DR	on	Th17	cells	was	not	 significantly	different	between	the	groups.	In	addition,	overall	changes	in	CD4+	T	cell	frequencies	and	activation	did	not	significantly	differ	by	vaginal	CT	category	(data	not	shown).			
Figure	 3.3.	 Proportion	 and	 phenotype	 of	 Th17	 cells	 stratified	 according	 to	







































































































IQR	and	range)	of	Th17	counts	(first	graph),	Th17	frequencies	(second	graph)	and	CCR5	expression	on	Th17	cells	(third	graph).	(Bottom	panel)	Expression	of	activation	markers	CD38	 and	HLA-DR	 on	Th17	 cells,	 and	 co-expression	 of	 CCR5	 together	with	 activation	markers	on	Th17	cells.	Mann-Whitney	and	Kruskal-Wallis	 tests	were	used	to	compare	groups.	P<0.05	were	considered	significant.	ns=not	significant.			
3.4.4 Relationship	 between	 L.	 crispatus	 (C2)	 and	 L.	 iners	 (C3)	
CTs	and	Th17	cell	frequencies/activation	status		
Although	both	Lactobacillus	spp.	are	commonly	found	colonizing	the	lower	FRT	in	 healthy	 women,	 L.	 crispatus	 colonization	 has	 been	 reported	 to	 be	 more	beneficial	 than	L.	iners	(Verstraelen	 et	 al.,	 2009).	 Therefore,	 the	 frequency	 and	phenotype	of	Th17	 cells	were	 compared	 in	 a	 subset	of	 the	non-C1	adolescents	(focusing	on	those	who	did	not	have	any	STIs;	n=31).	Of	these,	42%	(13/31)	had	an	L.	crispatus-dominated	VMB	(C2),	and	58%	(18/31)	had	an	L.	iners-dominated	(C3)	 VMB.	 Adolescents	with	 C2	 and	 C3-type	 VMBs	 had	 similar	 relative	 counts	and	 frequencies	of	cervical	Th17	cells	 (Figure	3.4).	Although	there	was	a	 trend	towards	reduced	activation	of	Th17	cells	(co-expression	of	CD38	and	HLA-DR)	in	adolescents	who	had	an	L.	iners-dominated	CT	(C3)	compared	to	those	with	an	L.	





expression	 in	 adolescents	with	L.	 crispatus-	 (C2;	 orange	 circles)	 versus	L.	 iners-
dominated	microbiota	(C3;	pink	circles).	(Top	panel)	Th17	counts,	Th17	frequencies,	and	 CCR5	 expression	 on	 Th17	 cells.	 (Bottom	panel)	 Expression	 of	 activation	markers	CD38	 and	HLA-DR	 on	Th17	 cells,	 and	 co-expression	 of	 CCR5	 together	with	 activation	markers	on	Th17	cells.	The	bar	represent	the	median,	the	error	bars	represent	the	IQR.	Mann-Whitney	U	test	was	used	to	compare	groups.	P<0.05	were	considered	significant.	ns=not	significant.			
3.4.5 Impact	 of	 BV	 status	 and	 vaginal	 CT	 clustering	 on	 genital	
cytokine	profiles		







































































































IL-10	 (p=0.03,	 p.	 adj=0.04)	 concentrations	 were	 significantly	 higher	 in	adolescents	with	an	intermediate	Nugent	score	compared	to	BV+	adolescents.		Similarly,	 adolescents	 with	 C2	 (L.	 crispatus)	 and	 C3	 microbiota	 (L.	 iners)	 had	significantly	 lower	 Th17-related	 cytokine	 concentrations	 compared	 to	 those	with	a	C1	microbiota	(more	diverse;	Figure	3.6).	Interestingly,	the	concentration	of	IL-1β	was	three	times	higher	in	adolescents	with	L.	iners-	(C3)	compared	to	L.	
crispatus-dominated	 VMB	 (C2)	 (1.67	 pg/ml	 vs	 0.43	 pg/ml,	 respectively,	p=0.001).	Genital	tract	IL-1β	concentrations	also	tended	to	be	six	times	higher	in	adolescents	with	 intermediate	Nugent	 scores	 compared	 to	 those	with	BV	 (217	pg/ml	vs	35	pg/ml;	Figure	3.5),	although	this	was	not	significant.	
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Because	condom	use	and	the	presence	of	vaginal	yeast	differed	according	to	BV	status	(see	 Table	 3.1),	 the	 associations	 between	 Th17-related	 cytokines	 and	 BV	 were	evaluated	using	a	multivariate	logistic	regression	in	order	to	adjust	for	these	potential	confounders	 (Figure	 3.7).	 After	 adjusting	 for	 STIs,	 IL-17A	 (I	 [intermediate]:	 β=2.52,	CI=1.38-3.67;	BV+:	β=0.90,	CI=0.15-1.65),	IL-17F	(I:	β=1.67,	CI=0.90-2.44;	BV+:	β=1.16,	CI=0.64-1.68),	 IL-6	 (I:	 β=1.70,	 CI=0.95-2.45;	 BV+:	 β=1.21,	 CI=0.69-1.74),	 IL-1β	 (I:	β=2.22,	CI=1.45-2.98;	BV+:	β=1.80,	CI=1.21-2.39),	 IL-23	 (I:	β=1.05,	CI=0.45-1.66;	BV+:	β=0.75,	CI=0.36-1.14),	IL-33	(I:	β=1.14,	CI=0.25-2.02;	BV+:	β=1.15,	CI=0.58-1.72),	TNF-α	(I:	β=1.97,	CI=1.19-2.74;	BV+:	β=1.65,	CI=0.15-1.65),	IL-4	(I:	β=1.14,	CI=0.45-1.83;	BV+:	β=1.06,	CI=0.54-1.58),	IL-25	(I:	β=1.08,	CI=0.43-1.74;	I:	BV+:	β=1.08,	CI=0.65-1.51)	and	IFN-γ	 (I:	 β=1.17,	 CI=0.06-2.27;	 BV+:	 β=1.09,	 CI=0.39-1.79)	 cytokines	 remained	positively	 associated	 with	 both	 having	 intermediate	 Nugent	 scores	 and	 being	 BV+.	Further	 adjusting	 condom	 use	 and	 yeast	 infections,	 IL-17A	 (I:	 β=3.67,	 CI=0.90-2.44;	BV+:	β=1.32,	CI=0.40-2.23),	IL-17F	(I:	β=1.81,	CI=0.77-2.85;	BV+:	β=1.52,	CI=0.88-2.16),	IL-6	(I:	β=2.02,	CI=1.06-2.97;	BV+:	β=1.65,	CI=0.93-2.36),	IL-1β	(I:	β=2.10,	CI=1.23-2.98;	BV+:	β=1.93,	CI=1.26-2.61),	IL-23	(I:	β=0.96,	CI=0.27-1.65;	BV+:	β=0.85,	CI=0.41-1.30),	TNF-α	 (I:	 β=1.61,	 CI=0.77-2.45;	 BV+:	 β=1.80,	 CI=1.15-2.45),	 IL-4	 (I:	 β=1.05,	 CI=0.29-1.81;	BV+:	β=1.18,	CI=0.62-1.74),	IL-25	(I:	β=1.05,	CI=0.30-1.80;	BV+:	β=1.21,	CI=0.71-1.71)	 and	 sCD40L	 (I:	 β=0.83,	 CI=0.15-1.52;	 BV+:	 β=0.43,	 CI=0.04-0.83)	 remained	significant	for	both	BV	intermediate	and	positive.		
	































































































Figure	3.7.	Multivariate	 logistic	 regression	analysis	of	 the	 relationships	between	Th17-
related	 cytokines	 in	 adolescents	 with	 intermediate	 Nugent	 scores	 (orange)	 and	 those	
who	were	BV+	(black)	adolescents	(compared	to	BV-	adolescents),	adjusting	for	potential	




Figure	 3.8.	 Correlation	 between	 IL-10	 and	 IL-17A	 (blue	 dots)	 or	 IL-17F	 (black	 dots)	
concentrations	 (top	 panels)	 and	 IL-17:IL10	 ratios	 (bottom	 panels),	 measured	 in	 BV	
negative,	 intermediate	 and	BV	positive	 adolescents.	Box	 and	whisker	 plots	 represent	 the	median,	IQR	and	range.	Only	significant	p-values≤0.05	are	displayed	on	the	graphs,	in	blue	(IL-17A)	or	black	text	(IL-17F).		
	
	
3.4.6 Relationship	 between	 L.	 crispatus-(C2)	 and	 L.	 iners-dominated	
(C3)	vaginal	CTs	and	Th17-related	cytokines		
To	 compare	 the	 impact	 of	 Lactobacillus	 dominated	 microbiota	 on	 genital	 cytokine	concentrations,	Th17-related	cytokines	(in	adolescents	without	STIs)	were	analysed	by	CT	 status.	 In	 the	 38	 AGYW	 included	 in	 this	 analysis,	 Th17-related	 cytokine	concentrations	were	similar	 in	the	two	Lactobacillus-dominated	CTs	(Figure	3.9),	with	the	exception	of	IL-21	which	tended	to	be	higher	in	AGYW	with	L.	crispatus-dominated	microbiota	 (3.30	 pg/ml)	 than	 those	 with	 L.	 iners-dominated	microbiota	 (0.08	 pg/ml,	p=0.26;	Figure	3.9A).	Similarly,	there	was	a	trend	towards	decreased	concentrations	of	IL-1β	in	adolescents	with	L.	crispatus-dominated	vaginal	microbiota	(p=0.03,	p.	adj=0.4;	Figure	3.9B).			































































































































(orange	 bars)	or	 L.	 iners-dominated	microbiota	 (pink	 bars).	 (A)	 Cytokines	 produced	 by	Th17	cells.	(B)	Other	cytokines	involved	in	the	differentiation	and	regulation	of	Th17	cells.	Box	and	 whiskers	 represent	 the	 median,	 IQR	 and	 range.	 Only	 significant	 p-values	 of	 ≤0.05	 are	displayed.			
3.4.7 Relationship	between	Nugent-BV	 and	Th17	 cells	 and	 cytokines	
in	the	presence	of	chlamydia	infection	
Since	asymptomatic	chlamydia	infection	alone	increased	IL-17A	genital	concentrations	(Chapter	2,	Figure	2.11),	and	it	was	highly	prevalent	in	this	cohort	(33%),	the	impact	of	BV	on	Th17	cells	in	the	presence	or	absence	of	chlamydia	was	investigated.	BV	positive	adolescents	with	chlamydia	(in	the	absence	of	other	STIs;	BV+C+)	were	compared	to	BV	positive	 adolescents	without	 any	 STIs,	 including	 chlamydia	 (BV+C-),	 adolescents	who	had	no	BV	and	STIs	(BV-C-),	and	those	who	only	had	chlamydia	(BV-C+).	Frequencies	of	






































































































** ** *** ***
****
********








The	 vaginal	 microbiome	 is	 likely	 to	 interact	 with	 local	 genital	 tract	 immunity	 and	epithelial	barrier	 function	 in	 the	FRT,	 and	alterations	 in	 this	microbiome,	 such	as	BV,	have	 been	 linked	 to	 increased	 HIV	 susceptibility	 to	 HIV	 infection	 (Low	 et	 al.,	 2011;	Cohen	et	al.,	2012;	Gosmann	et	al.,	2017;	McClelland	et	al.,	2018).	 In	 this	Chapter,	 the	impact	 of	BV	and	an	 altered	VBM	on	Th17	 cells,	 the	 cytokines	 they	produce	 and	 that	regulate	 them	were	explored	 in	AGYW,	at	risk	 for	HIV	acquisition.	BV+	adolescents	as	well	 as	 those	who	had	 intermediate	Nugent	 scores	 (4-6)	had	higher	vaginal	pHs	 than	BV-	adolescents,	in	addition	to	having	more	diverse	C1	CT,	defined	by	fewer	lactic	acid	producing	 lactobacilli	 (Lennard	 et	 al.,	 2017).	 BV+	 adolescents	 reported	 less	 regular	condom	use,	although	they	were	also	less	likely	to	have	yeast	infections	by	Gram	stain.	Hutchinson	 et	 al.	 (2007)	 similarly	 reported	 that	 more	 consistent	 condom	 use	 was	associated	with	decreased	incidence	of	BV	in	women	whom	they	followed	for	a	total	of	3	 years.	 	Moreover,	 van	de	Wijgert	 (2007)	 and	 colleagues	 reported	 a	 strong	negative	association	between	BV	and	vaginal	yeast.		Previous	 studies	 that	 characterized	 the	 VMB	 in	 African	 women	 (African	 American	women	from	the	US	and	women	currently	living	in	Africa)	showed	that	fewer	of	these	women	 tended	 to	 have	 Lactobacillus-dominated	 microbiota,	 but	 rather	 had	 more	diverse	 microbiota	 compared	 to	 women	 of	 North	 American	 and	 European	 women	(Ravel	et	al.,	2011;	Anahtar	et	al.,	2015;	Bayigga	et	al.,	2018;	Lennard	et	al.,	2017).	As	others	 from	our	group	have	previously	 reported	 in	AGYW	from	 the	same	community,	the	VMB	of	adolescents	in	this	study	clustered	into	three	CTs	(Lennard	et	al.,	2017):	just	over	 half	 had	C1-dominated	VMBs	 in	which	 vaginal	 swabs	were	 characterized	 by	 the	presence	 of	 Gardnerella	 and	 other	 anaerobic	 bacterial	 species;	 while	 the	 rest	 of	 the	AGYW	had	VMBs	classified	as	either	C2	(dominated	by	L.	crispatus)	or	C3	(dominated	by	
L.	 iners).	 Furthermore,	 adolescents	 who	 were	 BV+	 or	 who	 had	 intermediate	 Nugent	scores	had	a	predominantly	C1	VMB,	with	the	most	abundant	species	being	G.	vaginalis,	
BVAB1,	Megasphaera,	L.	iners	 and	Prevotella	spp.,	while	BV-	adolescents	primarily	had	either	L.	crispatus	(C2)	or	L.	iners	(C3)	dominated	microbiota.			
	 98	
Th17	cells	are	thought	to	play	a	critical	role	in	destroying	extracellular	bacteria	(Carey	et	 al.,	 2016;	 Cosorich	 et	 al.,	 2017),	 although	 they	 are	 also	 highly	 susceptible	 to	 HIV	infection	(McKinnon	et	al.,	2015;	Stieh	et	al.,	2016).	In	this	cohort,	neither	the	frequency	nor	activation	status	of	Th17	cells	(defined	by	being	CCR6+	and	CCR10-	CD4+	T	cells)	differed	 by	 BV	 status	 or	 VMB	 CT	 classification.	 This	 data	 suggests	 that	 vaginal	CCR6+CCR10-	 Th17	 cells	 were	 not	 altered	 by	 BV	 nor	 the	microbiome	 in	 this	 cohort.	Although	no	previous	studies	have	evaluated	the	interplay	between	the	VMB	and	genital	Th17	cells,	conflicting	results	have	emerged	on	the	impact	of	BV	on	genital	tract	CD4+	T	cell	 frequencies.	While	 some	 studies	 found	 that	 vaginal	 dysbiosis	was	 not	 associated	with	any	change	in	genital	CD4+	T	cell	frequencies	or	activation	status	(Lennard	et	al.,	2017),	others	have	reported	increased	frequencies	and	more	activated	CD4+	T	cells	in	women	with	BV	or	vaginal	dysbiosis	(Rebbapragada	et	al.,	2008;	Thurman	et	al.,	2015;	Gosmann	et	al.,	2017).	In	this	study,	the	overall	frequency	of	CD4+	T	cells	and	activation	of	these	cells	were	also	not	altered	in	adolescents	with	BV	or	dysbiosis.			Since	 several	 studies	 have	 reported	 that	 L.	 crispatus	 is	 more	 beneficial	 than	 L.	 iners	(Borgdorff	et	al.,	2015;	Gautam	et	al.,	2015;	Petrova	et	al.,	2017),	the	phenotype	of	Th17	cells	 in	 adolescents	 with	 an	 L.	 crispatus	 were	 compared	 to	 those	 with	 an	 L.	 iners-dominated	 VMB,	 in	 the	 absence	 of	 any	 confounding	 common	 STIs	 (including	 C.	
trachomatis,	 N.	 gonorrhoeae,	 M.	 genitalium,	 or	 T.	 vaginalis).	 The	 frequency	 and	activation	 status	 of	 cervical	 Th17	 cells	 did	 not	 differ	 significantly	 in	 AGYW	 with	 L.	
crispatus-	and	L.	iners-dominated	VMBs,	those	with	L.	iners-dominated	VMBs	tended	to	be	less	activated	than	those	with	L.	crispatus-dominated	VMBs.			It	was	 interesting	 to	note	 in	 this	study	 that	AGYW	with	L.	iners-dominated	microbiota	(C3)	 tended	 to	 have	 higher	 genital	 concentrations	 of	 IL-1β	 than	 adolescents	 with	 L.	
crispatus-dominated	 VMBs	 (C2).	 None	 of	 the	 other	 cytokines	 produced	 by	 Th17	 cells	(including	IL-17A,	IL-17F,	IL-21	and	IL-22),	or	others	involved	in	Th17	differentiation	or	regulation	appeared	to	differ	by	Lactobacilli	group.	IL-1β	is	also	thought	to	be	important	in	driving	the	differentiation	of	Th17	cells	(Lasigliè	et	al.,	2011),	although	adolescents	with	an	L.	iners-dominate	VMB	had	similar	frequencies	of	Th17	cells	with	those	with	an	
L.	 crispatus-dominated	 microbiota	 in	 this	 cohort.	 Previous	 in	 vitro	 studies	 have	suggested	 that	 L.	 crispatus	 inhibits	 inflammatory	 cytokine	 responses,	 which	 may	 be	
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important	in	the	context	of	lowering	HIV	risk	(Rizzo	et	al.,	2015;	Chetwin	et	al.,	2019).	A	recent	 study	 from	our	 group	 in	 adolescents	 from	 the	 same	 community	 in	Cape	Town	reported	 that	 a	 L.	 iners-dominated	 VMB	 was	 not	 associated	 with	 an	 inflammatory	cytokine	profile	compared	to	those	with	a	L.	crispatus-dominated	VMB	(Lennard	et	al.,	2017).	 The	 role	 of	 L.	 iners	 in	 vaginal	 health	 is	 unclear,	 since	 it	 is	 detected	 in	 normal	conditions	as	well	 as	during	vaginal	dysbiosis	 (Petrova	et	 al.,	 2017).	 Several	previous	studies	have	considered	L.	crispatus	 and	L.	iners	 to	 largely	be	 functionally	similar,	and	both	outcompete	other	vaginal	commensals	for	resources,	a	survival	strategy	needed	to	maintain	 a	 healthy	 vaginal	 microbiota	 (Yamamoto	 et	 al.,	 2009;	 France	 et	 al.,	 2016).	Others	have	also	argued	that	L.	iners	might	be	more	adaptable	to	survive	in	a	dysbiotic	vaginal	 state	 compared	 to	 L.	 crispatus,	 and	 might	 help	 to	 facilitate	 recovery	 to	 a	lactobacilli-dominated	microbial	community	(Ferris	et	al.,	2004;	Jakobsson	and	Forsum,	2007;	 Srinivasan	 et	 al.,	 2010;	 Lambert	 et	 al.,	 2013;	 Petrova	 et	 al.,	 2017).	 Of	 all	 the	
Lactobacillus	spp.	that	typically	colonize	the	lower	FRT,	L.	iners	has	the	smallest	genome	size	 (~1.3Mbps;	 Macklaim	 et	 al.,	 2011).	 In	 their	 comprehensive	 description	 of	 the	 L.	
iners	 genome,	 Macklaim	 and	 co-authors	 (2011)	 reported	 that	 766	 genes	 predicted	within	L.	iners	 genome	were	 shared	between	L.	crispatus,	L.	acidophilus	 and	L.	gasseri,	although	these	“core”	genes	represent	>60%	of	the	L.	iners	coding	sequence	compared	to	 only	 37%	 of	 L.	crispatus,	 and	 44%	 of	 L.	acidophilus	 and	 L.	gasseri	 sequence	 space.	Further	 studies	 are	needed	 to	 investigate	whether	 the	 reason	L.	iners	 is	 also	 found	 in	women	with	vaginal	dysbiosis	is	because	of	its	adaptable	nature	and	its	greater	ability	to	 compete	 with	 other	 organisms	 compared	 to	 L.	 crispatus,	 or	 perhaps	 it	 has	 a	pathogenic	nature	that	is	driving	dysbiosis.		Effector	cytokines	are	central	mediators	of	Th17	immunity	(Ouyang	et	al.,	2012),	and	it	was	therefore	important	to	know	if	alterations	in	the	VMB	influenced	the	production	of	these	cytokines.	It	was	interesting	to	note	therefore	that	all	of	the	cytokines	measured	were	 elevated	 in	 BV+	 adolescents	 and	 those	 with	 intermediate	 Nugent	 scores	 (4-6)	compared	to	BV-	adolescents,	and	most	of	these	remained	significant	after	adjusting	for	multiple	comparisons,	STIs,	reported	condom	use	and	yeast	infections.	Furthermore,	it	was	 surprising	 that	 adolescents	with	 intermediate	 VMB	had	 higher	 concentrations	 of	genital	 IL-17A,	 IL-17F	 and	 IL-10	 compared	 to	 BV+	 adolescents.	 In	 BV+	 AGYW,	 IL-10	correlated	 positively	 with	 both	 IL-17A	 and	 IL-17F.	 Previous	 studies,	 focusing	 on	
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inflammatory	 cytokines	 and	 chemokines,	 reported	 that	 BV	 (Nugent	 7-10)	 and	intermediate	 VMB	 (Nugent	 4-6)	 induced	 similar	 magnitudes	 of	 FRT	 inflammation	(Hedges	et	al.,	2006;	Masson	et	al.,	2014;	Guédou	et	al.,	2014;	Deese	et	al.,	2015).			Since	 Amsel	 et	 al.	 (1983)	 first	 defined	 the	 clinical	 criteria	 for	 diagnosing	 BV,	 which	included	 vaginal	 pH>4.5	 for	 the	 detection	 of	 women	 with	 BV,	 vaginal	 pH	 has	 been	evaluated	as	a	sensitive	but	non-specific	tool	to	diagnose	vaginal	dysbiosis	(Hemalatha	et	 al.,	 2013).	 In	 this	 cohort,	 a	 vaginal	 pH	 of	 4.7	 was	 observed	 in	 BV-	 (Nugent	 0-3)	adolescents,	 which	 was	 higher	 than	 the	 normal	 vaginal	 pH	 of	 4.5	 or	 less	 that	 is	considered	 normal	 (Amsel	 et	 al.,	 1983;	 Ravel	 et	 al.	 2011).	 Although	 BV-	 AGYW	 had	vaginal	pHs	above	what	is	considered	normal	internationally,	it	was	interesting	to	note	that	 adolescents	 with	 BV	 (Nugent	 7-10)	 or	 intermediate	 VMBs	 (Nugent	 4-6)	 had	significantly	higher	vaginal	pHs	 compared	 to	 their	BV-	 counterparts.	 Previous	 studies	have	 reported	 a	 positive	 correlation	 between	 vaginal	 pH	 and	 abnormal	 vaginal	microbiota	(Caillouette	et	al.,	1997;	Ravel	et	al.,	2011;	Hemalatha	et	al.,	2013;	O’Hanlon	et	al.,	 2013;	Krauss-Silva	et	 al.,	 2014),	which	was	 supported	by	 the	 findings	 from	 this	Chapter.	 The	 composition	 of	 the	 microbial	 ecosystem	 undoubtedly	 influences	 the	vaginal	pH	and	vice	versa.	Lactobacillus	species	have	been	shown	to	produce	lactic	acid,	which	 is	required	to	maintain	this	 low	vaginal	pH	(Tachedjian	et	al.,	2017;	Chetwin	et	al.,	 2019).	 In	 this	 adolescent	 cohort,	 vaginal	 pH	 was	 not	 associated	 with	 changes	 in	Th17-related	cytokines.		In	support	of	the	Nugent	scoring	analysis,	adolescents	in	this	study	with	more	diverse	vaginal	 microbiota	 (belonging	 to	 C1	 CT)	 also	 had	 elevated	 Th17-related	 cytokines	compared	to	those	with	L.	crispatus-	(C2)	or	L.	iners-dominated	VMB	(C3).	Gosmann	et	al.	(2017)	also	found	that	Th17-related	cytokines	IL-17,	IL-1β,	and	IL-23	were	elevated	in	 women	 with	 high	 diversity,	 low	 Lactobacillus	 abundance	 vaginal	 bacterial	communities.	 Anahtar	 et	 al.	 (2015)	 showed	 that	 altered	 vaginal	 microbiota	 increase	genital	inflammation	by	pattern	recognition	receptors	sensing	of	pathobionts	by	vaginal	epithelial	and	mucosal	antigen	presenting	cells	(APC).	Lower	Th17-related	cytokines	in	adolescents	with	Lactobacillus-dominated	microbiota	 (C2	 and	 C3)	 compared	 to	 those	with	 C1	 VMBs	 may	 also	 be	 a	 result	 of	 immune-regulatory	 properties	 of	 vaginal	
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lactobacilli	and	their	metabolites	like	lactic	acid	(Spurbeck	and	Arvidson,	2011;	Hearps	et	al,	2017).			









4.1 Abstract	Several	 studies	 have	 suggested	 that	 HCs	 may	 increase	 susceptibility	 to	 HIV	acquisition	in	women.	AGYW	in	SA	continue	to	be	at	a	heightened	risk	of	acquiring	HIV	compared	to	adolescent	boys	or	young	men.	Biological	mechanisms	are	likely	to	 contribute	 significantly	 to	 this	 high	 risk,	 including	 the	 number	 and	 activation	status	of	HIV	target	cells	available	in	the	lower	genital	tract	to	become	infected	in	adolescent	girls.	Since	Th17	cells	are	highly	susceptible	to	HIV	infection	compared	to	other	CD4+	T	subsets,	the	aim	of	this	Chapter	was	to	evaluate	whether	this	T	cell	subset	 and	 their	 related	 cytokines	 were	 altered	 in	 the	 FRT	 of	 adolescents	randomized	to	various	HC	methods,	including	NuvaRing,	NET-EN	and	COCPs.	One	hundred	and	 thirty	adolescent	girls	were	enrolled	and	 randomized	 to	one	of	 the	three	HCs.	After	four	months,	participants	crossed	over	to	another	HC	for	another	four	months	before	exiting	the	study.	In	an	intra-individual	analysis	at	crossover,	NuvaRing	 use	 was	 associated	 with	 increased	 proportions	 of	 cervical	 Th17	 cells	that	 expressed	 activation	markers	HLA-DR/CD38,	 despite	 decreased	 frequencies	of	Th17	cells	overall	compared	to	NET-EN	and	COCPs	use.	In	addition,	adolescents	on	 NuvaRing	 had	 increased	 concentrations	 of	 cervical	 Th17-related	 cytokines,	including	 IL-21,	 IL-1β,	TNF-α	and	IFN-γ.	Contraceptive	arms	at	crossover	did	not	differ	 by	 activation	 or	 chemokine	 receptor	 expression	 by	 cervical	 Th17	 cells,	although	 an	 increase	 in	 Th17-related	 cytokines	 (IL-21,	 IL-1β,	 IL-33,	 IL-4,	 TNF-α,	IFN-γ	and	sCD40L)	in	participants	on	NuvaRing	was	noted.	No	difference	in	genital	tract	 concentrations	 of	 Th17-related	 cytokines	 was	 noted	 between	 NET-EN	 and	COCPs	 users.	 Together,	 this	 data	 suggest	 that	 the	 use	 of	 the	 inserted	 vaginal	NuvaRing	 alters	 the	 frequency	 of	 Th17	 cells	 at	 the	 genital	 mucosa	 and	 Th17-related	cytokines	to	a	greater	extent	than	NET-EN	and	COCPs.							
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4.2 Introduction	It	 is	 undisputable	 that	 HCs	 are	 important	 in	 preventing	 unwanted	 pregnancies	(Kallner	 and	Danielsson,	2016).	The	 synthetic	progestins	DMPA	and	NET-EN	are	widely	 used	 in	 SSA	 because	 of	 their	 relatively	 long-acting	 nature,	 compared	 to	other	contraceptives	like	COCPs	which	need	to	be	taken	daily	(Heffron	et	al.,	2012;	UNDESA,	2015).	NET-EN	is	administered	bi-monthly,	while	DMPA	is	administered	every	 third	 month.	 Because	 of	 affordability,	 DMPA	 has	 been	 a	 popular	 product	offered	 in	 the	 public	 sector	 in	 developing	 countries,	 although	 NET-EN	 is	increasingly	being	used	at	higher	costs.			Despite	 the	 contraceptive	 benefits,	 there	 is	 public	 health	 concern	 that	 injectable	contraceptives	increase	a	woman’s	susceptibility	to	HIV	(Polis	et	al.,	2016).	It	has	been	 estimated	 that	 injectable	HCs	may	be	 responsible	 for	 up	 to	 130	000	HIV-1	infections	 per	 year	 globally	 (Butler	 et	 al.,	 2013).	 The	World	Health	Organization	recently	 reviewed	 their	 guidelines	 on	 the	 medical	 eligibility	 of	 DMPA	 for	contraceptive	use	and	stated	that	women	at	high	risk	for	HIV	acquisition	should	be	informed	of	 the	uncertainty	 regarding	 injectable	 contraceptives	 (WHO,	2015).	 In	support	 of	 this	 recommendation,	 the	 first	 multi-center,	 open-label,	 randomized	trial	 of	 DMPA	 versus	 other	 contraceptive	 methods	 (levonorgestrel	 implant	 and	copper	IUD)	on	HIV	outcomes	–	called	the	Evidence	for	Contraceptive	Options	and	HIV	Outcomes	(ECHO)	-	 is	under	way	and	the	eagerly	awaited	results,	which	will	be	announced	later	this	year,	will	provide	more	information	on	HIV	susceptibility	with	 the	 use	 of	 HCs	 (http://echo-consortium.com).	 Some	 of	 the	 biological	mechanisms	by	which	DMPA	use	is	thought	to	increase	HIV	susceptibility	include	suppression	 of	 local	 protective	 immunity,	 alteration	 in	 protective	 Lactobacilli-dominated	 vaginal	 microbiota,	 and	 elevated	 levels	 of	 mucosal	 inflammatory	cytokines	which	could	result	in	an	influx	of	HIV	target	cells	to	the	genital	mucosa	(Ghanem	et	al.,	2005;	Chandra	et	al.,	2013).		In	 contrast	 to	 injectable	 contraceptives	 like	 DMPA,	 a	 recent	 systematic	 review	found	 that	 COCPs	 did	 not	 similarly	 increase	 HIV	 risk	 (Polis	 et	 al.,	 2016).	 In	addition,	 this	 review	 also	 suggested	 that	 the	 available	 data	 on	 NET-EN	 do	 not	suggest	an	association	with	HIV	risk	in	women,	although	the	trend	was	positive.	In	
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a	population	that	has	a	high	HIV	prevalence,	it	is	important	to	answer	the	question	whether	HCs	increases	HIV	acquisition	and	provide	safer	options	for	women.	With	a	 variety	 of	 options	 to	 choose	 from,	 women	 should	 be	 able	 to	 make	 informed	decisions	 regarding	 the	 type	 of	 contraception	 to	 choose.	 The	 use	 of	 safe	 and	effective	 contraceptives	 in	 regions	 at	 the	 highest	 risk	 for	 HIV	 infections,	particularly	in	AGYW	is	a	global	health	priority.			NuvaRing®	 (containing	 etonogestrel	 and	 ethinyl	 estradiol),	 a	 hormonal	 vaginal	ring	 placed	 in	 the	 cervix	 for	 three	 weeks,	 has	 been	 recently	 licensed	 for	 use	 in	South	Africa,	adding	another	HC	option	for	women	in	South	Africa.	This	combined	contraceptive	vaginal	ring	(CCVR)	has	previously	been	found	to	increase	“healthy”	




This	 cohort	 was	 a	 sub-study	 to	 an	 NIH-funded	 parent	 study	 called	 “Choices	 for	Adolescent	 Prevention	 Methods	 for	 South	 Africa	 (CHAMPS)”	 which	 aimed	 to	evaluate	 the	 acceptability,	 feasibility,	 and	 adherence	 to	 various	 HC	 choices	 in	AGYW,	with	the	view	to	extend	this	to	preferences	for	HIV	prevention	modalities	as	 more	 HIV	 prophylactic	 products	 are	 developed	 (PI:	 Prof	 Linda-Gail	 Bekker,	Desmond	 Tutu	 HIV	 Foundation,	 UCT).	 The	 study	 design	 was	 an	 open-label,	randomized	crossover	study	of	130	sexually	active	 female	adolescents	aged	15	–	19	years	from	Masiphumelele,	Cape	Town,	South	Africa.	Inclusion	criteria	included	being	HIV-negative,	non-pregnant,	seeking	hormonal	contraceptives	or	a	change	in	method,	 and	 willing	 to	 refrain	 from	 inserting	 non-study	 vaginal	 products	 or	objects	into	the	vagina	for	the	duration	of	the	study.	Exclusion	criteria	included	not	being	 sexually	 active,	 being	 HIV	 positive,	 having	 any	 symptomatic	 STIs	 or	 an	abnormal	Pap	smear,	a	positive	urine	pregnancy	test,	being	contra-indicated	to	any	study	 product,	 or	 if	 informed	 consent	 (adolescents	 ≥18	 years)	 or	 assent	 with	parental	consent	(adolescents	<18	years)	was	not	obtained.		After	the	screening	visit,	adolescents	who	met	the	inclusion	and	exclusion	criteria	returned	 within	 40	 days	 for	 enrolment	 into	 this	 study.	 After	 enrolment,	adolescents	were	randomly	assigned	in	a	1:1:1	ratio	to	one	of	the	three	study	arms,	according	to	the	following	schema	(Figure	4.1):		
• Arm	 1:	 Adolescents	 received	 injectable	 NET-EN	 (intramuscular	 injection	containing	200mg	of	progestogen	norethisterone	oenanthate)	once	every	8	weeks	for	4-months.	
• Arm	 2:	 Adolescents	 received	 the	 CCVR	 NuvaRingâ	 (Merck,	 Sharp	 and	Dohme,	 containing	 0.12mg	 etonogestrel	 and	 0.015mg	 ethinyl	 estradiol)	inserted	for	three	weeks	continuously	followed	by	one	ring	free	week	for	a	4-month	period.	The	 study	 clinicians	 carried	out	 vaginal	 examination	 and	removed	the	used	rings	(as	requested	by	participants).	
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A	rapid	HIV	test	(Alere	DetermineTM	HIV-1/2	Ag/Ab	Combo;	Alere,	MA,	USA)	and	pregnancy	 test	 (U-test	 Pregnancy	 strip;	 Humor	 Diagnostica,	 Pretoria,	 SA)	 was	performed	 at	 all	 study	 visits	 (screening,	 enrolment,	 crossover	 and	 exit).	 If	 HIV	seroconversion	 occurred	 during	 the	 study,	 the	 participant	 was	 counselled	 and	referred	for	HIV	management	while	being	allowed	to	continue	her	participation	in	the	study.			
4.4.3 Sample	collection	




vaginalis	 and	M.	genitalium,	as	 described	 in	 section	 2.3.3.	 BV	 was	 diagnosed	 by	Gram	staining	using	Nugent’s	criteria,	as	described	in	section	2.3.4.		
4.4.5 Hormone	measurement	
Blood	 was	 collected	 using	 SST	 tubes	 to	 measure	 serum	 hormone	 levels.	Concentrations	of	E2,	LH	and	FSH	were	measured	in	blood	specimens,	which	was	measured	by	BARC,	as	described	previously	in	section	2.3.3.		
4.4.6 Flow	cytometry		
An	 endocervical	 cytobrush	 (Digene®	 Corporation)	 was	 collected	 from	 each	participant	 under	 speculum	 examination,	 and	 processed	 within	 4	 hours	 as	previously	 described	 in	 section	 2.3.4.	 CMCs	 were	 stained	 with	 the	 following	monoclonal	 antibodies:	 CD3,	 CCR6,	 CCR5	 (BD	 Biosciences);	 CD38	 (eBioscience);	CD4	 (Invitrogen);	 CD8,	 CCR10,	 HLA-DR	 (Biolegend)	 as	 previously	 described	 in	section	 2.3.5.	 A	 DUMP	 channel	 consisting	 of	 CD14,	 CD19	 (Invitrogen)	 and	 ViVid	(Life	 Technologies)	 was	 included	 to	 remove	 monocytes,	 B-cells	 and	 dead	 cells.	Th17-like	 cells	 were	 considered	 as	 those	 that	 expressed	 CCR6	 but	 not	 CCR10,	while	highly	activated	T	cells	were	considered	as	 those	that	expressed	CD38	and	HLA-DR.	CCR5	was	 included	as	 the	major	HIV	co-receptor	 involved	 in	viral	entry	during	 sexual	 transmission	 (Lopalco,	 2010).	A	 representative	 figure	 showing	 the	gating	strategy	is	shown	in	Chapter	2,	section	2.3.7.		
4.4.7 Cytokine	measurements	
The	concentrations	of	Th17-related	cytokines,	including	IL-17A,	IL-22,	IL-21,	IL-1β,	IL-4,	IL-6,	IL-10,	IL-17F,	IL-23,	IL-25,	IL-31,	IL-33,	IFN-γ,	sCD40L	and	TNF-α,	were	measured	 as	 described	 in	 section	 2.3.9,	 using	 the	 Bio-Plex	 Pro™	 Human	 Th17	cytokine	Luminex	kit	(Bio-Rad	Laboratories	Inc).	
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4.4.8 Statistical	analyses	




One	 hundred	 and	 fifty-six	 adolescents	 were	 screened	 for	 this	 study.	 Of	 these,	130/156	 were	 enrolled.	 Of	 those	 that	 did	 not	 enroll,	 21/156	 (13%)	 were	 not	interested	 in	 the	 study,	 and	 5/156	 (3%)	 did	 not	 meet	 the	 enrolment	 criteria.	Reasons	for	not	including	these	five	adolescents	included	that	they	were	younger	than	15	years	at	the	time	of	screening	(n=1),	were	on	TB	treatment	(n=1),	anaemic	(n=1),	had	elevated	blood	pressure	(n=1),	or	raised	liver	function	(n=1).	The	130	adolescents	 who	 where	 eligible	 and	 enrolled	 were	 randomized	 to	 the	 three	hormonal	 contraceptive	 arms,	 with	 45/130	 being	 randomized	 to	 NuvaRing,	45/130	 to	 NET-EN,	 and	 40/130	 to	 COCPs	 (Figure	 4.2).	 Of	 these,	 108/130	completed	 visit	 2	 (83%),	 and	 93/130	 completed	 the	 final	 visit	 (72%).	 One	participant	assigned	to	the	NET-EN	arm	seroconverted	before	the	crossover	visit	and	mucosal	sampling	was	not	performed	at	the	crossover	and	exit	visits,	and	one	participant	withdrew	consent	 for	mucosal	 sample	collection	at	 the	exit	visit.	The	final	numbers	was	thus	107	at	crossover	and	92	at	exit.	A	total	of	nine	adolescents	deviated	 from	 the	 protocol:	 In	 the	 NuvaRing	 arm,	 one	 participant	 changed	 to	COCPs	and	three	changed	to	NET-EN	before	the	crossover	visit;	in	the	COCPs	arm,	one	 participant	 changed	 to	 NuvaRing	 and	 three	 changed	 to	 NET-EN	 before	 the	crossover	 visit;	 in	 the	 NET-EN	 arm,	 one	 participant	 deviated	 from	 protocol	 by	changing	 to	 COCPs.	 Some	 of	 the	 reasons	 for	 changing	 methods	 included	 poor	adherence	 (mainly	 in	 the	COCPs	arm),	discomfort	with	 study	product	 (mainly	 in	the	NuvaRing	arm)	and	spotting	(in	the	NET-EN	arm).		The	baseline	characteristics	of	the	cohort	are	summarized	in	Table	4.1.	There	was	no	 difference	 in	 baseline	 characteristics	 across	 arms	 (including	 age,	 endogenous	hormone	level,	BMI,	vaginal	pH,	genital	 infections,	BV,	prior	use	of	contraception,	sexual	 risk	 behaviour	 and	 intra-vaginal	 insertion	 practices).	 Although	 the	 initial	intent	was	to	recruit	adolescents	who	were	naïve	to	HCs	into	the	study,	very	few	adolescents	 in	 this	 age	 group	 in	 this	 community	 were	 not	 currently	 using	 HCs	(5/130).	As	a	result,	 the	protocol	had	to	be	amended	to	 include	adolescents	who	were	 otherwise	 eligible	 and	 considering	 method	 change,	 of	 whom	 none	 had	
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previously	used	NuvaRing	prior	to	study	initiation.	Within	the	age	group	enrolled,	the	majority	 of	 the	 adolescents	were	 not	 contraceptive	 naïve	 at	 enrolment,	with	the	majority	previously	using	NET-EN	(56%).				
	
Figure	4.2.	Flow	diagram	showing	number	of	the	adolescents	screened,	enrolled	and	




























NuvaRing	n=45	 NET-EN	n=45	 COCPs	n=40	 P-value	Median	age	at	screening	 17	(16	–18)	 17	(16	–18)	 17	(16	–18)	 0.91	
Serum	hormone	concentration	
	 	 	 				E2	(pmol/l)	 97.0	(63.0–138.0)	 106.0	(85.2–157.8)	 90.5	(75.5–137.0)	 0.46				FSH	(U/L)	 4.7	(2.8–5.8)	 4.7	(3.6–5.8)	 5.5	(4.2–6.2)	 0.08				LH	(IU/l)	 4.4	(2.0–5.9)	 4.5	(2.0	–6.5)	 4.0	(2.0–5.4)	 0.93	BMI	(kg/m2)	 25.0	(22.1–27.8)	 25.0	(22.5–29.1)	 25.7	(21.5–28.3)	 0.75	Vaginal	pH	 4.7	(4.4–5.2)	 5.0	(4.7–5.3)	 4.7	(4.4–5.2)	 0.33	
Genital	infections	at	screening	
	 	 	 	
			Any	STIs	 19	(42.2%)	 22	(48.9%)	 15	(37.5%)	 0.48	
			Chlamydia	trachomatis	 14	(31.1%)	 17	(37.7%)	 12	(30.0%)	 0.70	
			Neisseria	gonorrhoeae	 5	(11.1%)	 5	(11.1%)	 3	(7.5%)	 0.97	
			Trichomonas	vaginalis	 4	(8.8%)	 5	(11.1%)	 4	(10.0%)	 0.75	
			Mycoplasma	genitalium	 0	(0.0%)	 2	(4.4%)	 1	(2.5%)	 0.36				HSV-2	serology	 12	(26.7%)	 13	(28.8%)	 14	(35.0%)	 0.49				Presence	of	yeast	hyphae	 10	(22.2%)	 4	(8.8%)	 6	(15.0%)	 0.22	
BV	status	
	 	 	 0.69				BV-	(Nugent	0-3)	 23	(51.1%)	 18	(40.0%)	 20	(48.8%)	 				Intermediate	(Nugent	4-6)	 3	(6.6%)	 7	(15.6%)	 4	(9.8%)	 				BV+	(Nugent	7-10)	 19	(43.2%)	 20	(44.4%)	 16	(40.0%)	 	
Prior	contraceptive	method	
	 	 	 0.44				Naive	 2	(4.4%)	 2	(4.4%)	 1	(2.5%)	 				Not	currently	 6	(13.3%)	 10	(22.2%)	 10	(25.0%)	 				DMPA	 5	(11.1%)	 7	(15.9%)	 7	(17.5%)	 				NET-EN	 28	(62.2%)	 21	(46.7%)	 20	(50.0%)	 				COCPs	 3	(6.7%)	 2	(4.5%)	 1	(2.5%)	 				Implanon	 1	(2.2%)	 2	(4.5%)	 0	(0.0%)	 	
Sexual	risk	behaviour	
	 	 	 				Age	of	sexual	debut	 15	(14	–16)	 15	(14	–16)	 15	(14	–16)	 0.97				Condom	use	always			 61.4%	 61.9%	 60.9%	 0.99				Multiple	sexual	partners	 0	(0.0%)	 1	(2.2%)	 0	(0.0%)	 1.00				Number	of	sexual	partners	 1	(1-1)	 1	(1-2)	 1	(1-1)	 0.16	
Vaginal	practices	















































































C y t o k i n e s	
produced	 by	Th17	cells	 C y t o k i n e s	involved	 in	 Th17	differentiation	 C y t o k i n e s	involved	 in	regu la t ing	Th17	cells	
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Figure	4.3.	Comparison	of	genital	Th17-related	cytokines	at	baseline,	stratified	by	
study	 arm.	Based	 on	 their	 functional	 relatedness	 to	 Th17	 cells,	 cytokines	 have	 been	divided	into	those	produced	by	Th17	cells	(first	column;	including	IL-17A,	IL-17F,	IL-21,	IL-22),	and	those	involved	in	their	differentiation	(second	column;	including	IL-6,	IL-1β,	IL-23,	IL-33,	TNF-α)	and	those	involved	in	their	regulation	(third	column;	including	IL-4,	IL-10,	 IL-25,	 IL-31,	 IFN-γ).	 Pink	 boxes	 indicate	 adolescents	 randomized	 to	 NuvaRing,	blue	boxes	indicate	adolescents	randomized	to	NET-EN,	and	green	boxes	indicate	those	randomized	 to	 COCPs.	 A	 Mann-Whitney	 U	 test	 was	 used	 to	 compare	 medians	 with	p≤0.05	being	considered	significant.	No	significant	differences	were	noted.			
4.4.3 Baseline	genital	Th17	cell	frequencies	and	activation	did	
not	differ	by	study	arm	prior	to	randomization	
The	phenotype	and	 level	of	activation	of	genital	mucosal	Th17	cells	at	baseline	was	initially	characterized	to	confirm	that	Th17	cells	did	not	differ	by	study	arm,	prior	to	randomizations.	The	cell	count	(per	cytobrush)	and	relative	frequency	of	Th17	 cells	 (of	 total	 CD4+	 T	 cells)	 was	 the	 same	 across	 arms,	 with	 an	 overall	median	 frequency	 of	 54.0%	 (IQR	 44.0%	 -	 64.3%;	 Figure	 4.4)	 being	 R6+R10+	(Th17-like).	 Expression	 of	 CCR5	 and	 activation	 markers	 (CD38,	 HLA-DR)	 was	also	similar	across	arms	(data	not	shown).			
	
Figure	4.4.	Comparison	of	Th17	cell	frequency	and	number	at	baseline,	according	


























randomized	to	NET-EN,	and	green	boxes	indicate	those	randomized	to	COCPs.	The	box	and	 whisker	 plots	 show	 the	 median	 (middle	 line),	 IQR	 (boxes)	 and	 whiskers	 extend	between	 the	 minimum	 and	 maximum	 values.	 A	 Mann-Whitney	 U	 test	 was	 used	 to	compare	medians	with	 a	 p	 value	 of	 ≤0.05	 being	 considered	 significant.	No	 significant	differences	were	noted.			
4.4.4 Impact	of	HC	arm	on	genital	Th17-related	cytokine	
concentrations:	the	crossover	visit		
Adolescents	were	randomized	to	one	of	the	three	HC	products	for	four	months,	returning	 to	 the	 clinic	 for	 an	 HC	 crossover	 visit.	 The	 following	 ITT	 and	 PP	analyses	focused	on	the	crossover	visit,	where	measurements	were	made	before	the	 adolescents	 crossed	over	 to	 another	product.	 In	 the	 ITT	analysis,	 data	was	analysed	according	to	randomization,	while	in	the	PP	analysis,	data	was	analysed	according	to	the	actual	HC	the	participants	were	on	(detailed	in	section	4.3.8).		Alteration	of	cytokines	in	the	genital	tract	may	have	significant	effect	on	HIV	risk	in	women	(Masson	et	al.,	2015a;	Passmore	et	al.,	2016;	McKinnon	et	al.,	2018).	Of	the	 cytokines	produced	by	Th17	 cells	 (IL-17A,	 IL-17F,	 IL-21,	 IL-22),	 IL-21	was	significantly	 elevated	 in	 genital	 secretions	 in	 adolescents	 who	 used	 NuvaRing	(p=0.009;	 Figure	 4.5A).	 In	 addition,	 several	 of	 the	 cytokines	 involved	 in	differentiation	 and	 regulation	 of	 Th17	 cells	 (including	 IL-1β	 [p=0.007],	 IL-33	[p=0.04],	 IL-4	 [p=0.02],	 TNF-α	 [p=0.01],	 IFN-γ	 [p=0.01],	 and	 sCD40L	 [p=0.02])	were	 significantly	 elevated	 in	 genital	 secretions	 from	 adolescents	 using	NuvaRing	 (Figure	 4.5B	 and	 C).	 IL-21,	 IL-1β,	 IFN-γ	 and	 TNF-α	 remained	significant	 after	 adjusting	 for	 multiple	 comparisons.	 Adjusting	 for	 protocol	violations	(early	change	in	HC),	the	PP	analysis	showed	similar	results	(data	not	shown).			In	 contrast	 to	 NuvaRing,	 NET-EN	 and	 COCPs	 use	was	 not	 associated	with	 any	significant	 changes	 in	 Th17-related	 cytokine	 concentrations	within	 individuals	before	 and	 after	 randomization	 (Figure	 4.6	 and	 4.7,	 respectively).	 In	 an	 ITT	
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analysis	comparing	these	three	HCs	cross-sectionally	at	week	16,	adolescents	on	NuvaRing	 had	 elevated	 IL-17A	 (p=0.009),	 IL-17F	 (p=0.03),	 IL-21	 (p=0.03)	 and	IL-33	 (p=0.03)	 compared	 to	 those	 on	 NET-EN;	 while	 IL-21	 (p=0.04),	 IL-6	(p=0.03),	 IL-1β	 (p=0.03)	 and	 TNF-α	 (p=0.04)	were	 elevated	 in	 adolescents	 on	NuvaRing	 compared	 to	 those	 on	 COCPs	 (Appendix	 Table	 A2).	 None	 of	 these	observations	remained	significant	after	adjusting	for	multiple	comparisons.			
	
Figure	 4.5.	 Comparing	 genital	 concentrations	 of	 Th17-related	 cytokines	 before	
























































































































































































































































Figure	 4.6.	 Comparing	 genital	 concentrations	 of	 Th17-related	 cytokines	 before	




































































































































































































































Figure	 4.7.	 Comparing	 genital	 concentrations	 of	 Th17-related	 cytokines	 before	











































































































































































































































































































































































































































Figure	 4.9.	 Th17-related	 cytokines	 (A)	 those	 produced	 by	 Th17	 cells	 (B)	 those	
involved	 in	 the	 differentiation	 of	 Th17	 cells	 and	 (C)	 those	 involved	 in	 the	
regulation	of	Th17	 cells,	 in	 adolescents	 changing	 from	NuvaRing	 to	NET-EN	and	












































































































































	Figure	4.10.	Th17-related	cytokines	 (A)	 those	produced	by	Th17	cells	 (B)	 those	
involved	 in	 the	 differentiation	 of	 Th17	 cells	 and	 (C)	 those	 involved	 in	 the	
regulation	of	Th17	cells,	in	adolescents	changing	from	NuvaRing	to	COCPs	and	vice	












































































































































Figure	4.11.	Th17-related	 cytokines	 (A)	 those	produced	by	Th17	 cells	 (B)	 those	
involved	 in	 the	 differentiation	 of	 Th17	 cells	 and	 (C)	 those	 involved	 in	 the	
regulation	of	Th17	cells,	 in	adolescents	changing	from	NET-EN	to	COCPs	and	vice	
































































































































Figure	 4.12.	 Phenotype	 of	 Th17	 cells	 in	 participants	 who	 changed	 between	
different	HCs.	(A)	Participants	who	changed	from	NuvaRing	to	NET-EN	and	vice	versa.	Data	 from	 38	 participants	 is	 included.	 (B)	 Participants	 who	 changed	 from	 COCPs	 to	NuvaRing	 and	 vice	versa.	 Data	 from	 16	 participants	 is	 included.	 (C)	 Participants	 who	changed	 from	NET-EN	 to	COCPs	and	vice	versa.	Data	 from	19	participants	 is	 included.	Wilcoxon	 matched-pairs	 signed	 rank	 test	 was	 applied.	 Only	 significant	 p-values	 are	displayed	 on	 the	 graph,	 and	 those	 in	 bold	 remained	 significant	 after	 adjusting	 for	multiple	comparisons.	
A	

















































































































































































Changes	 in	 Th17	 cells	 and	 Th17-related	 cytokines	 with	 the	 use	 of	 HCs	 were	investigated	across	 the	 three	visits	 in	 all	 the	available	participants,	 and	also	 in	matched	participants	from	baseline	to	the	exit	visit,	to	evaluate	whether	the	shift	from	 one	 contraceptive	 method	 and	 back	 again	 influenced	 activation	 or	frequencies	 of	 Th17	 cells	 or	 changes	 in	 cytokine	 profiles.	 This	 longitudinal	analysis	focused	on	the	Th17-related	cytokines	that	changed	significantly	in	the	NuvaRing	arm	analyses	shown	 in	Figure	4.14	(including	 IL-17A,	 IL-21,	 IL-6,	 IL-1β,	IL-23,	IL-33,	IL-4,	IL-10,	IL-25,	IL-31,	IFN-γ,	TNF-α,	and	sCD40L).			







Figure	 4.13.	 Longitudinal	 changes	 in	 phenotype	 and	 activation	 of	 cervical	 Th17	
cells	in	adolescents	randomized	to	use	NuvaRing	first	and	then	either	crossing	to	




























































































































































































respectively;	 Figure	 4.14),	 and	 subsequently	 decreased	when	 they	 swopped	 to	NET-EN	 even	 after	 adjusting	 for	multiple	 comparisons	 (p=0.001,	 adj.	 p=0.006;	p=0.006,	adj.	p=0.02;	p=0.001,	adj.	p=0.006,	respectively).	This	same	pattern	was	observed	in	the	unmatched	analysis	for	these	three	cytokines	(IL-6,	IL-1β,	IL-33).	Genital	 concentrations	 of	 INF-γ	 also	 increased	 at	 week	 16	 after	 NuvaRing	 use	(p=0.04)	and	decreased	at	week	32	after	NET-EN	use	(p=0.003,	adj.	p=0.01)	 in	the	 matched	 analysis.	 Furthermore,	 adolescents	 had	 a	 significant	 decrease	 in	genital	concentrations	of	 IL-21	(p=0.001),	 IL-23	(p=0.009),	 IL-4	(p=0.01),	 IL-10	(p=0.006),	 IL-25	 (p=0.006),	 IL-31	 (p=0.001),	 TNF-α	 (p=0.006)	 and	 sCD40L	(p=0.05)	when	they	swopped	from	NuvaRing	to	NET-EN	in	the	matched	analysis,	and	they	remained	significant	after	adjusting	for	multiple	comparisons	except	for	IL-4	and	sCD40L.		
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Figure	 4.14.	 Longitudinal	 changes	 in	 Th17-related	 cytokine	 concentrations	 in	
adolescents	initially	randomized	to	NuvaRing	and	who	subsequently	crossed	over	












































































































































































































Wilcoxon	matched-pairs	sign	ranked	test.	Unmatched	samples	were	compared	using	a	Mann-Whitney	U	test	(baseline	n=24,	crossover	n=22,	exit	n=22).				In	adolescents	who	initially	used	NuvaRing	and	subsequently	swopped	to	COCPs,	no	significant	changes	in	genital	cytokine	concentrations	were	observed	(Figure	4.15).	Numbers	were	small	for	this	analysis	and	should	be	treated	with	caution	(n=4	 matched;	 n=7-8	 all).	 However,	 cytokine	 concentrations	 appeared	 to	 be	elevated	after	using	NuvaRing	for	16	weeks	and	these	appeared	to	be	lower	after	switching	 to	 COCPs	 for	 only	 a	 subset	 of	 cytokines	 (including	 IL-4,	 IL-10,	 IL-1β	and	sCD40L,	Figure	4.15),	although	not	significantly.		
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Figure	 4.15.	 Longitudinal	 changes	 in	 cervical	 Th17-related	 cytokine	




































































































































































to	 exit	 (n=4)	using	a	Wilcoxon	matched-pairs	 signed	 ranked	 test.	Unmatched	 samples	were	compared	using	a	Mann-Whitney	U	test	(baseline	n=7,	crossover	n=8,	exit	n=8).				







































































































































	In	adolescents	randomized	to	NET-EN	and	subsequently	swopped	to	NuvaRing,	no	 significant	 changes	 in	 genital	 cytokine	 concentrations	 were	 observed	compared	to	baseline,	and	when	they	swopped	over	to	NuvaRing	(Figure	4.17).	Although	IL-6	and	IL-33	tended	to	be	elevated	when	matched	participants	were	on	 NuvaRing	 at	 week	 32	 compared	 to	 week	 16	 and	 baseline.	 Due	 to	 a	 small	sample	size,	participants	changing	from	NET-EN	to	COCPs	were	not	investigated.	
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Figure	 4.17.	 Longitudinal	 changes	 in	 Th17-related	 cytokine	 concentrations	 in	
adolescents	initially	randomized	to	NET-EN	and	who	subsequently	crossed	over	to	





































































































































































































the	 three	 visits	 [baseline	 (0),	 crossover	 (16)	 and	 exit	 (32)]	 in	 adolescents	
randomized	 initially	 to	 use	 COCPs	 and	 who	 subsequently	 crossed	 over	 to	

































































































































	Figure	 4.19.	 Longitudinal	 changes	 in	 Th17-related	 cytokine	 concentrations	 in	
adolescents	initially	randomized	to	COCPs	and	who	subsequently	crossed	over	to	













































































































































































































4.5 Discussion	The	aim	of	this	Chapter	was	to	investigate	the	impact	of	various	HC	products	on	genital	tract	CD4+	T	cell	activation	and	numbers	in	adolescents,	in	a	randomized	crossover	trial	comparing	NuvaRing,	NET-EN	and	COCPs,	focusing	on	Th17	cells	because	they	are	thought	to	be	highly	susceptible	to	HIV	infection	(Brenchley	et	al.,	2008;	Kim	et	al.,	2013;	Stieh	et	al.,	2016).	This	may	provide	valuable	insight	into	mechanisms	 underlying	 increased	HIV	 risk	 in	 adolescent	 girls.	 One	 of	 the	major	 findings	 was	 that	 genital	 tract	 IL-21,	 IL-1β,	 TNF-α	 and	 IFN-γ	concentrations	were	elevated	in	those	randomized	to	use	NuvaRing	at	crossover	compared	 to	 baseline.	 In	 contrast,	 no	 such	 changes	 in	 genital	 tract	 cytokines	were	observed	in	adolescents	initially	randomized	to	NET-EN	or	COCPs.			One	of	 the	many	 functions	of	Th17-related	cytokines,	 including	 IL-17A,	 IL-17F,	IL-6,	 IL-23	and	 IL-1β	 is	 to	 recruit	Th17	cells	 to	mucosal	 surfaces	 including	 the	genital	tract	(Conti	et	al.,	2009;	Sandquist	and	Kolls,	2018).	Therefore,	how	HCs	altered	 the	 frequency	 and	 activation	 of	 Th17	 cells	 within	 individuals	 was	investigated.	Adolescents	using	NuvaRing	had	significantly	elevated	frequencies	of	 highly	 activated	 cervical	 Th17	 cells	 (expressing	 both	 CD38	 and	 HLA-DR),	although	 these	 were	 present	 at	 lower	 frequencies	 compared	 to	 baseline.	Frequencies	 of	 highly	 activated	 Th17	 cells	 also	 tended	 to	 be	 elevated	 in	adolescents	 initially	 randomized	 to	 NET-EN,	 although	 not	 after	 adjusting	 for	multiple	 comparisons.	 No	 differences	 in	 the	 frequency	 or	 activation	 status	 of	cervical	 Th17	 cells	 were	 observed	 in	 adolescents	 changing	 from	 NuvaRing	 to	COCPs	 or	 those	 changing	 from	 NET-EN	 to	 COCPs	 at	 crossover	 and	 exit	 visits.	Adolescents	 using	 COCPs	 tended	 to	 have	 a	 decreased	 frequency	 of	 Th17	 cells,	with	 a	 significant	 increase	 of	 CCR5	 expression	 on	 these	 cells	 compared	 to	baseline,	 although	 this	 was	 not	 confirmed	 in	 the	 paired	 analysis.	 Overall,	 this	data	 suggests	 that	 all	 three	 HCs	 investigated	 altered	 Th17	 cells	 in	 the	 genital	tract	compared	to	when	these	young	girls	came	into	the	study.		The	median	age	of	sexual	debut	in	this	cohort	was	15	years,	and	having	had	sex	at	 or	 before	 the	 age	 of	 16	 has	 been	 reported	 to	 be	 a	 strong	marker	 for	 future	poor	sexual	health	patterns	(Cavazos-Rehg	et	al.,	2010;	Zuma	et	al.,	2014).	Unlike	
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in	 older	 women,	 the	 underdeveloped	 cervix	 of	 adolescents	 is	 going	 through	physical	 changes	 including	 changes	 in	 the	 vaginal	 epithelium	 (Moscicki	 et	 al.,	1999).	In	addition,	adolescent	girls	are	at	a	stage	of	hormonal	changes	associated	with	 sex	 maturation.	 These	 changes	 in	 addition	 to	 initiating	 HCs	 might	 all	contribute	to	perturbations	seen	in	the	genital	tract.	In	this	study,	the	range	of	E2	serum	levels	(74-142	pmol/L)	were	lower	than	the	reported	reference	ranges	in	older	 women	 (161-774	 pmol/L;	 Smritee	 Dabee	 PhD	 thesis).	 It	 would	 be	interesting	 to	 see	 whether	 NuvaRing	 perturbs	 the	 vaginal	 immune	microenvironment	 in	older	women	at	 the	same	extent	seen	 in	adolescent	girls,	given	the	differences	in	their	biological	sexual	maturity	of	the	genital	tract.		Overall,	 the	 results	 observed	 in	 this	 study	 show	 elevated	 genital	 Th17-related	cytokine	 concentrations	 in	 adolescents	 using	 NuvaRing	 but	 not	 in	 those	 using	NET-EN	and	COCPs.	Amongst	the	cytokines	produced	by	Th17	cells	(IL-17A,	IL-17F,	IL-21	and	IL-22),	IL-17F	was	less	affected	by	the	use	of	NuvaRing.	Although	both	cytokines	play	a	critical	role	in	tissue	inflammation	by	inducing	the	release	of	 proinflammatory	 cytokines,	 IL-17F	 has	 been	 reported	 to	 be	 less	 potent	 at	inducing	cytokines	(Sueki	et	al.,	2008;	Ouyang	et	al.,	2012;	Brembilla	et	al.,	2018;	Glatt	et	al.,	2018).	Increased	Th17-related	cytokines	observed	when	participants	were	 on	NuvaRing	might	 suggest	 both	 hormonal	 and	mechanical	 responses	 to	the	copolymer	evatane	vaginal	ring	(forming	the	NuvaRing)	in	the	vagina.	Early	studies	suggested	local	leukocytic	inflammatory	responses	after	IUD	insertion	in	the	endometrium	and	 fallopian	 tubes	 (Moyer	and	Mishell,	1971).	Furthermore,	the	 presence	 of	 an	 LNG-IUD	 in	 the	 genital	 tract	 has	 been	 associated	 with	inflammatory	cytokines	including	IL-1β,	TNF-α,	IFN-γ,	GM-CSF,	and	IFN-α	in	the	endocervical	 canal	 (Shanmugasundaram	et	 al.,	 2016;	 Sharma	 et	 al.,	 2018),	 and	insertion	of	the	copper	IUD	was	associated	with	increase	in	IL-1α,	IL-1β,	IL-6	and	TNF-α	 (Sharma	 et	 al.,	 2018).	 This	 shows	 that	 changes	 in	 cytokines	 can	 be	induced	both	mechanically	and	hormonally.		With	elevated	inflammatory	cytokines	including	IL-1β	noted	in	adolescents	using	NuvaRing,	 one	 would	 expect	 increased	 numbers	 and/or	 frequencies	 of	 Th17	cells	or	total	CD4+	T	cells	in	these	participants.	It	was	therefore	surprising	that	
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the	overall	frequency	of	total	genital	CD4+	and	Th17-like	T	cells	were	reduced	in	adolescents	assigned	to	the	NuvaRing	arm.	Alteration	in	Th17	cells	was	observed	in	 all	 HCs	 compared	 to	 baseline,	 indicating	 that	 exogenous	 hormones	 partly	caused	these	perturbations.	Highly	activated	genital	tract	T	cells	are	more	likely	to	die	by	apoptosis	than	resting	T	cells	(Nkwanyana	et	al.,	2009),	and	one	could	hypothesize	that	the	reduction	in	frequencies	of	cervical	Th17	cell	in	adolescents	using	 NuvaRing	 and	 NET-EN	might	 reflect	 cell	 death	 of	 these	 highly	 activated	cells.	 IL-10,	 IL-25,	 IL-4	 and	 IFN-γ	 negatively	 regulate	 Th17	 cells,	 and	 these	cytokines	 might	 also	 contribute	 to	 the	 dramatic	 decrease	 in	 Th17	 cell	frequencies	 seen	 in	 the	 NuvaRing	 arm,	 in	 addition	 to	 other	 immune	 cells	including	Tregs	 not	measured	 in	 this	 study,	 but	 are	 known	 to	 be	 important	 in	suppressing	 Th17	 responses	 (Lee	 et	 al.,	 2015b).	 In	 one	 study,	 NuvaRing	 and	COCPs	 users	 were	 found	 to	 have	 reduced	 frequencies	 of	 CD207+	 Langerhans	cells	in	the	vagina	(Mitchell	et	al.,	2014).	Langerhans	cells	are	antigen-presenting	cells	 that	 are	 known	 to	 activate	 cutaneous	 Th17	 responses	 in	 response	 to	bacterial	infections	(Deckers	et	al.,	2018).	Perhaps	participants	on	NuvaRing	also	had	 a	 reduction	 in	 these	 antigen-presenting	 cells	 thereby	 decreasing	 the	presence	 of	 Th17	 cells	 at	 the	 genital	 tract.	 Furthermore,	 the	 vaginal	 ring	 is	recognized	as	a	foreign	object	in	the	lower	reproductive	tract,	thereby	inducing	microbial	and	 immune	changes.	The	 localised	hormones	delivered	directly	 into	the	vagina	by	NuvaRing	might	also	contribute	to	this	effect.		Hardy	 et	 al.	 (2017)	 recently	 reported	 that	 the	 NuvaRing	 acquires	 a	 complex	bacterial	 biomass	 after	 insertion,	 including	 several	 BV-associated	 bacterial	strains.	 They	 postulated	 that	 even	 though	 the	 delivered	 hormones	 from	NuvaRing	 increased	 the	 concentration	 and	 relative	 abundance	 of	 vaginal	
Lactobacillus	spp.,	metabolites	and	bacteriocins	produced	by	Lactobacillus	were	not	effective	against	a	poly	microbial	biofilm.	While	the	microbial	composition	of	the	 biofilms	 associated	 with	 CCVRs	 in	 this	 study	 was	 not	 determined,	 it	 is	possible	that	these	bound	microbial	products	on	the	ring	bind	to	TLRs	expressed	on	 different	 epithelial	 and	 immune	 cells	 including	 T	 cells	 and	 neutrophils,	thereby	 initiating	 cytokine	 and	 chemokine	 production.	 Although	 neutrophil	infiltration	was	 not	measured,	 Th17	 cells	 are	 known	 to	 recruit	 neutrophils	 by	
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producing	 IL-17A	 and	 IL-17F	 (Roussel	 et	 al.,	 2010;	 Schofield	 et	 al.,	 2016).	Activation	 of	 Th17	 cells	 has	 been	 reported	 to	 result	 in	 a	 large	 amount	 of	inflammatory	cytokine	production	including	IL-17A,	IL-17F,	IL-21	and	IL-22	and	this	 partially	 explains	 why	 NuvaRing	 had	 increased	 Th17-related	 cytokine	concentrations	due	to	highly	activated	Th17	cells	observed	(Tesmer	et	al.,	2008;	Ouyang	et	al.,	2012).	The	use	of	NuvaRing	had	been	reported	to	increase	vaginal	wetness,	and	some	have	 linked	 this	 to	 inflammation	due	 to	a	 slight	 increase	 in	vaginal	white	blood	cells	in	CCVR	users	(Schwan	et	al.,	1983;	Veres	et	al.,	2004).	Vaginal	wetness,	however,	was	not	determined	in	this	study.			Aside	from	CCVRs,	vaginal	rings	containing	HIV	drugs	have	also	been	assessed	as	pre-exposure	prophylaxis	(PrEP)	modalities,	although	genital	tract	immune	cells	are	typically	not	measured	in	these	clinical	studies	(Johnson	et	al.,	2012;	Smith	et	al.,	 2015;	Baeten	 et	 al.,	 2016).	However,	 insertion	of	 a	 silicon	 intravaginal	 ring	into	female	macaques	was	not	associated	with	inflammatory	cytokines	IL-6	and	IL-8.	 Both	 tenofovir-medicated	 and	 unmedicated	 rings	 in	macaques	 have	 been	shown	to	form	biofilms	(Gunawardana	et	al.,	2011).		This	 study	 has	 several	 limitations.	 Although	 the	 initial	 plan	 was	 to	 recruit	adolescents	 who	 are	 contraceptive	 naïve	 into	 the	 study,	 the	 age	 range	 of	 this	young	 cohort	 (15-19	 years)	 biased	 recruitment	 to	 those	 who	 were	 already	sexually	 active	 and	 had	 initiated	 HCs.	 Moreover,	 these	 participants	 were	recruited	 from	a	 family	planning	clinic	 rather	 than	 from	a	broader	community.	For	participants	<18	years	of	age,	the	recruitment	process	was	difficult,	as	they	had	 to	 get	 a	 parental	 consent	 and	 expose	 that	 they	 were	 sexually	 active	 in	 a	culture	 where	 it	 is	 not	 typically	 widely	 accepted.	 Importantly,	 there	 was	 no	washout	period	due	 to	 the	nature	of	 the	 study	assuring	 that	participants	were	protected	 from	 unwanted	 pregnancies.	 Sexual	 risk	 behaviour	 and	 vaginal	practices	was	self-reported,	however,	these	were	similar	across	HC	arms	thereby	excluding	 possible	 confounders.	 Another	 important	 limitation	 is	 the	 small	sample	 size,	 decreased	 further	 by	 sub-analyses,	 and	 hence	 underpowered	 to	detect	some	changes.		
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5.1 	Abstract	
Cytotoxic	CD8+	T	cells	are	the	primary	adaptive	immune	mechanism	responsible	for	 controlling	 HIV.	 Although	 it	 is	 widely	 accepted	 that	 Th17	 cells	 (CD4+)	 are	more	 susceptible	 to	HIV	 infection,	 a	 subset	 of	 CD8+	T	 cells	 are	 also	 capable	of	producing	IL-17	and	therefore	considered	T	cytotoxic	IL-17	cells	(Tc17	cells).	IL-17	 is	 associated	 with	 inflammation	 and	 Th17	 cells	 are	 susceptible	 to	 HIV	infection,	nonetheless,	the	relative	role	of	Tc17	cells	in	HIV	infection	and	risk	is	less	well	understood.	Here,	the	impact	of	HCs	on	CD8+	T	cells	generally	and	on	the	frequencies	of	Tc17	cells	(CD8+CCR6+)	was	investigated	in	adolescents.	In	a	paired-analysis	 comparing	 baseline	 to	 the	 crossover	 visit,	 adolescents	 using	NuvaRing	had	lower	frequencies	of	cervical	CD8+	T	cells,	which	expressed	lower	levels	 of	 HLA-DR,	 but	 had	 higher	 frequencies	 of	 CD38	 and	 CCR5/CD38.	Moreover,	 frequencies	 of	 Tc17	 cells	 were	 decreased	 in	 these	 adolescents.	Similarly	 to	 NuvaRing,	 adolescents	 using	 NET-EN	 had	 reduced	 frequencies	 of	CD8+	with	elevated	frequencies	expressing	CD38	and	CCR5/CD38,	and	reduced	HLA-DR,	 in	 addition	 to	 reduced	 Tc17	 frequencies.	 The	 use	 of	 COCPs	 was	associated	with	 reduced	 frequencies	of	Tc17	cells,	 and	 increased	expression	of	CCR5/CD38	 and	 reduced	 expression	 of	 HLA-DR	 on	 cervical	 CD8+	 T	 cells.	 In	adolescents	 changing	 between	 HCs,	 those	 using	 NuvaRing	 had	 decreased	frequencies	of	Tc17	cells	compared	to	when	the	same	participants	were	on	NET-EN	or	COCPs.	This	data	suggests	that	HCs	reduced	the	frequencies	of	Tc17	cells,	while	altering	activation	markers	on	CD8+	T	cells,	which	may	have	implications	for	mucosal	immune	control	in	relation	to	HIV	infection.									
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As	 described	 in	 Chapter	 4	 (section	 4.3.1),	 the	 study	 design	was	 an	 open-label,	randomized	crossover	study	of	130	sexually	active	female	adolescents	aged	15–19	years	from	Masiphumelele,	Cape	Town,	South	Africa.	Inclusion	and	exclusion	criteria	 are	 described	 in	 Section	 4.3.1.	 Adolescents	 were	 randomized	 1:1:1	 to	three	arms:	 (1)	 injectable	NET-EN;	 (2)	 the	CCVR	NuvaRingâ;	 or	 (3)	COCPs	 (as	described	 in	 Chapter	 4).	 After	 being	 randomized	 onto	 each	 of	 these	contraceptive	 methods	 for	 four	 months,	 participants	 crossed	 over	 to	 another	form	of	HC	(as	shown	in	Figure	4.1).	Participants	receiving	either	NET-EN	or	the	daily	COCPs	(Arm	1	and	Arm	3,	respectively)	for	the	first	16	weeks	of	the	study	switched	over	to	using	NuvaRing	(Arm	2),	while	participants	receiving	NuvaRing	as	 the	 first	method	were	 given	 the	 choice	between	either	NET-EN	or	 the	daily	COCPs	 as	 their	 second	 method.	 After	 a	 total	 of	 32	 weeks,	 the	 participants	returned	for	a	final	visit	at	the	clinic	and	exited	the	study.		
5.3.2	HIV	and	pregnancy	testing	
As	described	 in	 Chapter	 4	 (section	 4.3.2),	 a	 rapid	HIV	 test	 (Alere	DetermineTM	HIV-1/2	Ag/Ab	Combo;	Alere,	MA,	USA)	 and	pregnancy	 test	 (U-test	 Pregnancy	strip;	 Humor	 Diagnostica,	 Pretoria,	 SA)	 was	 performed	 at	 all	 study	 visits	(screening,	enrolment,	crossover	and	exit).			
5.3.3	Sample	collection	
An	 endocervical	 cytobrush	 (Digene	 Corporation,	 MD,	 USA)	 was	 collected	 for	CMCs,	which	were	analysed	using	flow	cytometry	(section	2.3.5	and	2.3.6).		
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5.3.4	Flow	cytometry		
Endocervical	 cytobrushes	 (Digene®	 Corporation)	 were	 collected	 from	 each	adolescent	 under	 speculum	 examination,	 and	 processed	 within	 4	 hours	 as	previously	 described	 in	 section	 2.3.5.	 CMCs	 were	 stained	 with	 the	 following	monoclonal	antibodies:	CD3,	CCR6,	CCR5	(BD	Biosciences);	CD38	(eBioscience);	CD4	 (Invitrogen);	 CD8,	 CCR10,	HLA-DR	 (Biolegend)	 as	 previously	 described	 in	section	2.3.5.	A	DUMP	channel	consisting	of	CD14,	CD19	(Invitrogen)	and	ViVid	(Life	Technologies)	was	 included	 to	 remove	monocytes,	 B-cells	 and	dead	 cells.	The	gating	strategy	is	described	in	Chapter	2,	section	2.3.6.		
5.3.5	Statistical	analyses	





















































































































































































































































































































































































































































Figure	 5.2.	 Comparison	 of	 the	 frequency	 and	 activation	 status	 of	 cervical	 CD8+	 T	 cells	
from	adolescents	using	NuvaRing	(pink	circles),	NET-EN	(blue	circles)	and	COCPs	(green	
circles).	 Tc17	 cells,	 CCR5	 and	 activation	 markers	 were	 analysed	 within	 the	 CD8+	 T	 cell	population.	 The	 middle	 line	 represents	 the	 median,	 and	 the	 error	 bars	 represent	 the	 IQR.	Groups	were	compared	using	the	Kruskal-Wallis	test.			
5.4.2	Analysis	of	CD8+	T	cell	frequencies	and	activation	after	changing	
between	NuvaRing	to	NET-EN	


























































































































The	phenotype	of	CD8+	T	cells	 in	adolescents	changing	between	COCPs	and	NuvaRing	was	 investigated	 (Figure	5.4).	 The	 frequency	 of	 CD8+	T	 cells	 expressing	HLA-DR	was	significantly	 lower	 when	 adolescents	 used	 NuvaRing	 compared	 to	 when	 they	 were	using	COCPs,	in	a	matched	analysis	(p=0.02).	In	contrast,	the	frequency	of	CD8+	T	cells	expressing	 both	 CCR5/CD38	 was	 significantly	 elevated	 (p=0.003)	 when	 participants	were	 using	 NuvaRing	 compared	 to	 COCPs.	 In	 addition,	 Tc17	 cells	 were	 significantly	reduced	after	NuvaRing	use	(p=0.0003).			
Figure	 5.4.	 Comparison	 of	 cervical	 CD8+	 T	 cell	 phenotype	 and	 activation	 status	 in	






















































































































While	 the	 frequencies	 of	 cervical	 CD8+	 T	 cells	 expressing	 HLA-DR	 was	 significantly	higher	when	adolescents	were	using	NET-EN	compared	 to	when	 the	 same	adolescent	were	 using	 COCPs	 (p=0.004),	 the	 frequency	 of	 CD8+	 T	 cells	 expressing	 CCR5/CD38	together	was	significantly	lower	(p=0.0008).	Moreover,	Tc17	cells	were	increased	when	the	same	participants	used	NET-EN	(p=0.001;	Figure	5.5).			
Figure	 5.5.	 Comparison	 of	 cervical	 CD8+	 T	 cell	 frequencies	 in	 adolescents	 changing	

















































































































matched-pair	 signed	 rank	 test.	 P≤0.05	 were	 considered	 significant	 and	 those	 that	 were	significant	are	shown.			
5.4.5	Longitudinal	changes	in	CD8+	T	cells	across	all	three	study	visits	
Finally,	changes	in	CD8+	T	cell	frequencies	and	activation	between	baseline,	crossover	and	exit	were	assessed	to	determine	whether	profiles	that	were	changed	in	response	to	a	 particular	 HC	 reverted	 to	 pre-HC	 phenotypes	 after	 that	 particular	 HC	 was	discontinued.	As	shown	in	the	previous	analyses	(Figure	5.1A),	NuvaRing	use	appeared	to	 decrease	 both	 Tc17	 and	 total	 CD8+	 T	 cell	 frequencies	 in	 adolescents	 compared	 to	pre-NuvaRing	 (0	week)	baseline.	 It	was	 therefore	 interesting	 to	 assess	whether	 these	returned	to	baseline	levels	after	the	adolescents	swopped	to	NET-EN	or	COCPs.		NuvaRing	use	decreased	Tc17	cell	 frequencies	 (visible	at	 crossover	visit).	These	Tc17	cell	 frequencies	 did	 not	 return	 to	 baseline	 frequencies	 after	 adolescents	 changed	 to	NET-EN	 (p<0.0001	 compared	 to	baseline;	Figure	5.6A),	 and	Tc17	 cells	 at	 the	NET-EN	use	time	point	(week	32)	were	comparable	to	 frequencies	at	 the	NuvaRing	time	point	(week	 16).	 Similarly,	 frequencies	 of	 Tc17	 cells	 were	 not	 restored	 in	 those	 swopping	from	NuvaRing	to	COCPs	(p=0.03	compared	to	baseline;	Figure	5.6B),	and	Tc17	cells	at	the	COCPs	use	time	point	(week	32)	were	comparable	to	 frequencies	at	 the	NuvaRing	time	point	(week	16).	However,	it	should	be	noted	that	only	four	participants	on	COCPs	at	week	32	were	available	for	this	comparison.					
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Figure	5.7.	 Comparison	of	 cervical	 CD8+	T	 cells	 at	 baseline	 (0	weeks,	 n=17),	 crossover	
(16	weeks,	n=18)	and	exit	visit	(32	weeks,	n=21)	for	adolescents	initially	randomized	to	
NET-EN	 (until	 16	 weeks)	 and	 who	 subsequently	 crossed	 over	 to	 NuvaRing	 (until	 32	






























































































Figure	5.8.	 Comparison	of	 cervical	 CD8+	T	 cells	 at	 baseline	 (0	weeks,	 n=22),	 crossover	
(16	weeks,	n=21)	and	exit	visit	(32	weeks,	n=15)	for	adolescents	initially	randomized	to	






























































































5.5 Discussion	In	 this	chapter,	 the	effect	of	NuvaRing,	NET-EN	and	COCPs	on	overall	cervical	CD8+	T	cells	 and	 Tc17	 cell	 subsets	 in	 the	 reproductive	 tracts	 of	 adolescent	 females	 was	evaluated.	Baseline	 frequencies	 and	 activation	of	CD8+	T	 cells	were	 similar	 across	 all	arms,	 confirming	 that	 randomization	was	 effective	 in	 excluding	possible	 confounders.	Overall	frequencies	of	Tc17	and	CD8+	T	cells	were	reduced	in	NuvaRing,	while	only	the	frequency	of	Tc17	cells	 in	NET-EN	and	COCPs	users	were	reduced	by	16	weeks	of	HC	use.	 While	 the	 expression	 of	 CD38	 on	 CD8+	 T	 cells	 was	 only	 reduced	 within	 the	NuvaRing	 arm,	 all	 HCs	 had	 a	 significant	 reduction	 in	 HLA-DR	 and	 an	 increased	expression	 of	 CCR5/CD38	 on	 their	 cervical	 CD8+	 T	 cells	 after	 16	 weeks.	 Therefore,	intra-individual	 analysis	 (where	 each	 young	woman	was	 her	 own	 control)	 suggested	that	all	three	HCs	altered	cervical	CD8+	T	cells,	although	neither	the	frequency	nor	the	activation	 of	 these	 cells	 differed	 between	 arms	 after	 16	 to	 32	 weeks	 of	 HC	randomization.		Furthermore,	 extending	 the	 intra-individual	 analysis	 of	 those	 adolescents	 who	subsequently	 changed	 from	 one	 HC	 form	 to	 another,	 they	 tended	 to	 have	 lower	frequencies	 of	 Tc17	 cells,	 and	 higher	 expression	 of	 CCR5,	 CD38,	 CCR5/CD38	 and	CCR5/HLA-DR	on	their	CD8+	T	cells	when	they	were	using	NuvaRing	compared	to	when	they	 swopped	 to	 NET-EN,	 although	 NET-EN	 use	 did	 not	 restore	 expression	 levels	 to	baseline.	 Similarly,	 those	 that	 changed	 from	 NuvaRing	 to	 COCPs	 also	 had	 lower	frequencies	 of	 Tc17	 cells	 reduced	 expression	 of	 HLA-DR	 and	 increased	 expression	 of	CCR5/CD38	on	their	CD8+	T	cells	when	they	were	on	NuvaRing,	although	swopping	to	COCPs	 did	 not	 appear	 to	 restore	 their	 CD8+	 T	 cell	 frequencies	 to	 baseline.	 In	participants	 changing	 from	 NET-EN	 to	 COCPs,	 there	 was	 a	 decrease	 in	 Tc17	 cells,	reduced	expression	of	HLA-DR	and	increased	expression	of	CCR5/CD38	on	CD8+	T	cells	when	participants	were	on	COCPs.	Although	NET-EN	and	COCPs	use	tended	to	have	less	impact	 on	 the	 frequency	 of	 Tc17	 cells	 than	NuvaRing,	 activated	 CD8+	T	 cells	 did	 not	return	to	baseline	levels	after	adolescent’s	swopped	to	NET-EN	or	COCPs.	This	suggests	that	 all	 progestin-based	 contraceptives	 increase	 activated	CD8+	T	 cells.	 Expression	of	activation	markers	 during	 HIV	 infection	 has	 differential	 significance,	 such	 that	 single	expression	of	HLA-DR	on	CD8+	T	cells	is	associated	with	a	better	survival	of	these	cells,	that	are	polyfunctional	and	have	higher	cytolytic	and	proliferative	ability	compared	to	
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HLA-DR+CD38+	CD8+	T	cells	(Saez-Cirion	et	al.,	2007;	Hua	et	al.,	2014;	Gonzalez	et	al.,	2016).	 On	 the	 contrary,	 CD38+	 CD8+	 T	 cells	 are	 prone	 to	 apoptosis,	 and	 have	 been	associated	 with	 residual	 HIV	 viral	 replication	 in	 patients	 on	 ART	 (Chun	 et	 al.,	 2004;	Miguel	 Benito	 et	 al.,	 2004).	 Whether	 these	 characteristics	 apply	 in	 HIV-uninfected	individuals	and	at	the	genital	mucosa	is	yet	to	be	investigated.		A	 consistent	 trend	 that	 was	 observed	 in	 this	 cohort	 was	 the	 reduction	 in	 Tc17	 cells	frequencies	observed	from	baseline	to	week	16	and	32	of	using	HCs,	irrespective	of	the	HC	that	was	being	used.	Implications	of	decreased	frequencies	of	Tc17	cells	in	women	are	 not	 yet	 known.	 Tc17	 cells	 (CD8+	 T	 cells	 that	 express	 CCR6,	which	 is	 involved	 in	lymphocyte	 mucosal	 homing)	 have	 been	 shown	 not	 to	 be	 cytotoxic	 upon	 antigen	recognition	 so	 they	do	not	 kill	 target	 cells;	 rather	 they	produce	 several	 inflammatory	cytokines	 including	 IL-17,	 IFN-γ,	 TNF-α,	 and	 IL-2,	 and	 largely	 have	 a	 similar	 cytokine	profile	to	Th17	cells	(Kondo	et	al.,	2009;	Srenathan	et	al.,	2016).			Several	studies	have	shown	that	the	presence	of	CD8+	T	cells	in	the	vagina	is	required	for	protection	against	various	viral	pathogens	such	as	HIV	and	HSV,	through	the	release	of	cytotoxic	granules	containing	perforin	and	granzymes	(Musey	et	al.,	1997;	Nelson	et	al.,	2011).	Anti-HIV	specific	CD8+	T	cells	are	crucial	in	controlling	viremia	by	increasing	responses	 to	 on-going	 viral	 replication	 (Keoshkerian	 et	 al.,	 2003).	 MPA	 have	 been	reported	 to	 reduce	 the	 capacity	of	CD8+	T	 cells	 to	 release	 lytic	 granules	 and	produce	IFN-γ	 (Cherpes	 et	 al.,	 2008).	 In	 support	 of	 this,	 increased	 endogenous	 progesterone	levels	 in	 pregnant	 women	 have	 been	 associated	 with	 hypermethylation	 of	 the	 IFN-γ	gene,	an	underlying	mechanism	reported	to	increase	susceptibility	of	pregnant	women	to	 intracellular	 pathogens	 during	 pregnancy	 (Yao	 et	 al.,	 2017).	 Since	 the	 Tc17	 cell	subset	appear	to	be	more	effective	at	cytokine	production	than	cytolytic	capacity,	their	reduction	 in	 the	 cervix	 might	 suggest	 lower	 production	 of	 cytokines	 by	 these	 cells,	including	IFN-γ	which	is	thought	to	be	indispensable	to	host	defense	against	pathogens	(Tajima	et	al.,	2011).	Although	Tc17	cells	cytokine	production	was	not	assessed	in	this	study.		Tc17	cells	have	been	defined	for	the	purposes	of	this	Chapter	as	CD8+	T	cells	expressing	CCR6,	as	have	several	previous	studies	(Kondo	et	al.,	2007,	2009).	However,	others	have	
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characterized	them	functionally	by	their	ability	to	produce	IL-17	directly	(Zhuang	et	al.,	2012;	Perdomo-Celis	et	al.,	2018).	As	IL-17	production	by	these	cervical	Tc17	cells	was	not	evaluated,	it	is	not	known	whether	the	Tc17	cells	detected	here	are	producing	IL-17.	Since	 an	 overall	 decrease	 of	 CCR6	 on	 CD4+	 and	 CD8+	 T	 cells	 was	 observed	 in	 the	NuvaRing	arm,	the	downregulation	might	be	part	of	a	regulation	process	caused	by	the	excessive	 production	 of	 Th17-related	 cytokines.	 CCR6	 deficient	 mice	 have	 impaired	mucosal	 but	 not	 systemic	 humoral	 responses	 to	 rotavirus	 infection	 in	 the	 intestinal	mucosa,	 elucidating	 the	 importance	 of	 this	 chemokine	 receptor	 in	 lymphocyte	homeostasis	at	mucosal	surfaces	(Cook	et	al.,	2000).	Thus,	reduced	expression	of	CCR6	cells	on	CD8+	T	cells	may	contribute	to	increased	susceptibility	to	pathogens	on	the	one	hand,	 although	 decreased	 expression	 of	 CCR6	 at	 the	 genital	 mucosa	 may	 blunt	 HIV	target	 cell	 recruitment	 and	 lower	 the	 inflammatory	 state	 of	 the	mucosa	 on	 the	 other	hand.	Furthermore,	 these	CCR6+	CD8+	T	cells	would	need	 to	be	 further	characterized	and	 compared	 to	 CCR6-	 CD8+	 T	 cells	 to	 differentiate	 the	 two	 subsets.	 Perdomo-Celis	and	colleagues	(2018)	recently	reported	higher	 IL-17	production	by	activated	CD8+	T	cells	(co-expressing	CD38	and	HLA-DR)	from	HIV-negative	individuals,	and	that	CD8+	T	cells	 from	 non-viremic	 HIV	 positive	 individuals	 tended	 to	 produce	 less	 IL-17	 after	polyclonal	stimulation.	Moreover,	their	study	reported	activated	CD8+	T	cells	to	be	the	main	source	of	IL-17	among	the	CD8+	T	cell	population.	Matched	analysis	in	Chapter	4	showed	 an	 increase	 in	 genital	 concentrations	 of	 IL-17A	 when	 adolescents	 were	 on	NuvaRing	compared	to	when	they	were	on	NET-EN	or	COCPS.	Increased	activated	CD8+	T	cells	might	be	one	of	the	many	reasons	why	adolescents	had	increased	Th17-related	cytokines	when	they	were	on	NuvaRing.		A	limitation	of	this	study	was	that	blood	was	not	stored	for	measuring	circulating	CD8+	T	cell	frequencies,	to	determine	whether	this	was	a	localised	effect	of	HCs	at	the	genital	mucosa,	or	more	a	general	effect	that	could	be	detected	in	the	blood.	One	study	found	women	using	COCPs	to	have	elevated	blood	CD8+	T	cells	compared	to	those	not	using	HCs	(Auerbach	et	al.,	2002).	It	was	also	not	possible	to	determine	whether	the	changes	in	total	CD8+	T	cells	or	Tc17	cells	that	were	observed	in	adolescent	girls	in	this	Chapter	related	to	their	young	age,	since	older	women	were	not	part	of	this	study.		
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6.1 Discussion	Adolescence	 is	 a	 time	 of	 significant	 endocrine	 and	 biomedical	 change	 in	 females,	associated	with	increased	production	of	female	sex	hormones	(estrogen,	progesterone,	Luitenizing	 and	 follicle	 stimulating	 hormones),	 development	 of	 secondary	 sexual	characteristics,	 menarche,	 and	 sexual	 debut	 (Sehested	 et	 al.,	 2000).	 Adolescent	 girls,	particularly	 in	 SSA,	 face	 double	 vulnerabilities	 of	 unintended	 pregnancies	 and	 HIV	infection.	Despite	 the	 enormous	 benefits	 offered	 by	HCs,	 public	 health	 concerns	 have	been	 raised	 because	 of	 the	 heightened	 risk	 to	 HIV	 seen	 in	 women	 using	 long-acting	injectable	 HCs	 (Polis	 et	 al.,	 2016;	 Hapgood	 et	 al.,	 2018),	 especially	 in	 SSA,	 where	injectable	HCs	are	a	popular	choice	(Kleinschmidt	et	al.,	2007,	UNDESA,	2015)	and	HIV	risk	is	highest	(UNAIDS,	2017).	While	HCs	are	particularly	necessary	in	adolescence,	to	prevent	unwanted	pregnancies,	it	is	also	critical	to	provide	advice	and	HC	options	that	do	 not	 increase	 risk	 for	 HIV.	 In	 light	 of	 these	 related	 mandates,	 the	 aim	 of	 this	dissertation	was	to	first	characterize	the	immune	environment	in	the	adolescent	genital	tract	focusing	on	highly	HIV	susceptible	Th17	cells	and	their	related	cytokines,	and	then	to	 investigate	 whether	 the	 use	 of	 injectable	 NET-EN,	 COCPs	 or	 NuvaRing	 (newly	introduced	into	SA)	influenced	either	the	frequency	or	activation	status	of	these	highly	susceptible	CD4+	T	cells.	Through	Chapters	2	to	5,	this	dissertation	revealed	four	major	findings:	(i)	that	Th17	cells	are	a	major	subset	in	the	genital	tract	of	adolescent	girls;	(ii)	that	 the	 presence	 of	 BV	 and	 vaginal	 dysbiosis	 did	 not	 alter	 cervical	 Th17	 cell	frequencies,	however	BV	appeared	to	significantly	increase	Th17-related	cytokines,	by	favouring	 a	 pro-inflammatory	 immune	 microenvironment;	 (iii)	 that	 the	 use	 of	 HCs	tended	 to	 decrease	 cervical	 Th17	 frequencies,	 however,	 NuvaRing	 also	 increased	activation	markers	 (HLA-DR+CD38+)	 on	 Th17	 cells,	 and	 also	 increased	 Th17-related	cytokines;	and	(iv)	All	HCs	reduced	the	frequencies	of	Tc17	cells,	and	they	all	affected	expression	of	activation	markers	on	CD8+	T	cells.		
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6.1.1	 Activated	Th17	 cells	 are	 a	major	 subset	 in	 the	 genital	 tract	 of	 adolescent	
girls	
	Susceptibility	to	HIV	infection	is	influenced	by	many	factors,	including	the	availability	of	target	 cells	 at	 the	 genital	 mucosa	 (Trifonova	 et	 al.,	 2014).	 Chapter	 2	 focused	 on	characterizing	the	highly	HIV	susceptible	Th17	cells	and	Th17-related	cytokines	in	the	lower	reproductive	tract	of	adolescent	girls.	Th17	cells	(defined	by	expression	of	CCR6	and	 absence	 of	 CCR10;	McKinnon	 et	 al.,	 2015)	were	 found	 to	 be	 a	major	CD4+	T	 cell	subset	 in	 cervical	 cytobrushes,	 followed	 by	 CCR6-CCR10-	 CD4+	 T	 cells	 (which	 are	thought	to	be	a	mixture	of	Th1	and	Th2	cells;	Zhong	et	al.,	2017).	Moreover,	Th17	cells	found	 in	 the	 genital	 tract	 were	 highly	 activated	 (expressing	 CD38	 and	 HLA-DR),	 and	expressed	 high	 levels	 of	 the	 CCR5	 receptor	 compared	 to	 CCR6-CCR10-	 CD4+	 T	 cells.	Although	Th22	cells	also	express	CCR6	like	Th17	cells,	CCR10	had	been	reported	to	be	preferentially	 expressed	 by	 these	 cells,	 allowing	 one	 to	 differentiate	 them	 from	Th17	cells	 (CCR6+CCR10-;	 Duhen	 et	 al.,	 2009;	 McKinnon	 et	 al.,	 2015).	 In	 vitro	 studies	confirmed	 that	 majority	 of	 CCR6+	 CD4+	 T	 cells	 produced	 IL-17,	 although	 it	 was	 not	stained	 for	 in	 this	 study.	 Moreover,	 other	 chemokines	 receptors	 such	 as	 CCR4	 and	CXCR3	not	measured	in	this	study	allows	for	sub-classification	into	Th17	and	Th1/Th17	subsets,	respectively	(Liu	and	Rohowsky-Kochan,	2008;	Alvarez	et	al.,	2013;	Rodriguez-Garcia	et	al.,	2014).			Different	 cytokines,	 including	 those	 produced	 by	 Th17	 cells,	 are	 involved	 in	 their	differentiation	and	regulation,	such	as	IL-21	and	IL-22	(Guglani	and	Khader,	2010).	All	Th17-related	 cytokines	 in	 the	 different	 classes	 were	 detected	 in	 the	 genital	 tract	including	 IL-17A	and	 IL-17F.	Although	overall	 frequencies	of	 cervical	Th17	cells	 (as	a	proportion	 of	 CD4+	 T	 cells)	 did	 not	 correlate	 with	 concentrations	 of	 Th17-related	cytokines	 measured	 in	 genital	 secretions,	 highly	 activated	 cervical	 Th17	 cells	(expressing	 CD38)	 correlated	 positively	 with	 several	 cytokines,	 including	 IL-17A,	 IL-17F,	 IL-6,	 IL-10	 and	 sCD40L.	 Activation	 of	 Th17	 cells	 is	 known	 to	 induce	 them	 to	produce	cytokines,	which	could	partly	explain	the	correlation	observed	in	this	study.	In	
vitro	studies	have	reported	endogenous	hormones	to	alter	immune	functions	(Correale	et	al.,	1998;	Kanda	and	Watanabe,	2003;	Fahey	et	al.,	2008;	Seillet	et	al.,	2011).	In	this	study,	genital	Th17-related	cytokines	did	not	correlate	with	serum	E2	and	LH,	however,	
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activated	Th17	cells	were	negatively	associated	with	these	hormones.	Interestingly,	the	presence	 of	 STIs	 (including	 C.	 trachomatis,	 N.	 gonorhoeae,	 M.	 genitalium	 and	 T.	
vaginalis)	 did	 not	 alter	 Th17	 cell	 frequencies	 or	 activation	 status,	 although	 IL-17A	concentrations	were	elevated.	In	contrast,	yeast	 infections	were	associated	with	lower	frequencies	of	cervical	Th17	cells.			
6.1.2	 BV	 and	 an	 altered	 vaginal	 microbiota	 are	 associated	 with	 increased	
concentrations	of	Th17-related	cytokines		








	The	 WHO	 called	 for	 more	 randomization	 trials	 to	 better	 understand	 how	 HCs,	particularly	 the	 long-acting	 progestin-only	 injectable	 products	 (like	 DMPA),	 increase	women’s	susceptibility	to	HIV	(WHO,	2015).	The	aim	of	Chapter	4	was	to	investigate	the	impact	of	the	injectable	NET-EN,	COCPs	and	NuvaRing	(newly	licensed	in	South	Africa)	on	 the	 immune	environment	of	 the	adolescent	FRT,	 focusing	on	Th17	cells	defined	 in	Chapters	2	and	3.	NuvaRing	use	was	accompanied	by	a	marked	decrease	in	frequencies	of	cervical	Th17	cells,	although	these	were	highly	activated	compared	to	when	the	same	individuals	joined	the	study.	Although	adolescents	on	NET-EN	and	COCPs	also	tended	to	have	reduced	Th17	cell	 frequencies	after	16	weeks	of	HC	use,	 the	changes	seen	in	the	NuvaRing	arm	were	more	substantial.	The	highly	activated	genital	tract	Th17	cells	seen	in	the	NuvaRing	are	more	likely	to	die	by	apoptosis	than	resting	T	cells	(Nkwanyana	et	al.,	2009),	which	could	explain	their	reduced	frequencies.	Little	is	known	of	how	CCR6	is	regulated	 on	 T	 cells;	 however,	 a	 stable	 expression	 of	 CCR6	 on	 human	 T	 cells	 is	associated	with	promoter	demethylation	(Steinfelder	et	al.,	2011).	Molecular	studies	are	needed	 to	 investigate	whether	 the	changes	seen	 in	NuvaRing	might	also	be	related	 to	DNA	methylation.	 In	 summary,	 the	 use	 of	 NuvaRing	 promoted	 highly	 activated	 Th17	cells,	although	the	frequencies	were	reduced.	These	findings	are	summarized	in	Figure	6.1	below.			
	
Figure	 6.1.	 Summary	 of	 cervical	 Th17	 cells	 changes	 observed	 in	 the	 genital	 tract	 of	






6.1.4	 Only	NuvaRing	altered	Th17-related	cytokines			Th17-related	 cytokines	were	 upregulated	 in	 the	 NuvaRing	 arm	 compared	 to	 NET-EN	and	 COCPs	 arms.	 Pro-inflammatory	 cytokines	 including	 IL-17A,	 IL-β,	 IL-6	 and	 TNF-α	were	among	the	elevated	Th17-related	cytokines	in	adolescents	using	NuvaRing	(Figure	6.2).	 These	 cytokines	 are	 involved	 in	 activation,	 differentiation	 and	 recruitment	 of	immune	 cells	 including	T	 cells,	 neutrophils,	DCs	and	macrophages	 to	 the	genital	 tract	(Dubin	 and	 Kolls,	 2008;	 Arnold	 et	 al.,	 2016;	 Revu	 et	 al.,	 2018).	 Other	 important	cytokines	and	chemokines	involved	in	the	Th17	pathway	such	as	TGF-β,	and	the	CCR6	ligand	MIP-3a	were	not	measured,	and	 this	would	have	provided	more	 insight	on	 the	effect	of	NuvaRing	on	these	cytokines.	Interesting,	IL-1β	that	positively	regulate	MIP-1a	was	 elevated	 in	 adolescents	 using	 NuvaRing.	 Therefore,	 elevated	 cytokines	 in	adolescents	on	NuvaRing	might	increase	adolescent’s	susceptibility	to	HIV	acquisition.				
	
Figure	6.2.	Summary	of	changes	seen	 in	 the	concentration	of	Th17-related	cytokines	 in	
the	genital	tract	of	adolescent	girls.	Cytokines	including	IL-17A,	IL-1β	and	IL-6	were	elevated	after	NuvaRing	use	compared	to	NET-EN	and	COCPs.					
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6.2 Limitations	and	future	directions		This	 study	 defined	 Th17	 cells	 by	 chemokine	 receptor	 expression	 (CCR6+CCR10-)	 as	opposed	 to	 cytokine	 production.	 It	 could	 be	 that	 CCR6+CCR10-	 Th17	 cells	measured	here	are	not	 all	 able	 to	produce	 IL-17,	 therefore	overestimating	 these	 cells.	However,	identifying	Th17	cells	using	cytokine	production	represent	technical	challenges	because	of	the	low	cell	yield	and	fragility	of	cervical	cells,	and	the	plasticity	of	Th17	cells	(Boily-Larouche	 et	 al.,	 2017).	 Although	 this	 study	 aimed	 to	 recruit	 contraceptive	 naïve	adolescents,	most	of	 the	study	participants	were	on	NET-EN	at	baseline,	and	this	may	have	biased	the	study.	In	addition,	most	of	these	young	adolescents	had	asymptomatic	BV	 and	 STIs.	 However,	 given	 the	 randomized	 nature	 of	 this	 study,	 there	 was	 equal	distribution	between	arms	on	previously	used	methods	of	contraception,	BV	and	STIs.	The	 vaginal	 microbiome	 forms	 part	 of	 another	 PhD	 study,	 and	 was	 therefore	 not	presented	in	Chapter	4	and	5,	which	could	have	explained	some	of	the	differences	seen	between	 contraceptive	 arms.	 Self-reported	 behavioural	 data	 was	 limited,	 as	 some	adolescents	anecdotally	reported	to	have	tempered	with	their	rings,	and	this	might	have	contributed	to	the	high	inflammation	observed	with	the	use	of	NuvaRing.				The	main	disadvantage	of	a	crossover	study	is	the	potential	for	carry	over	between	the	HC	 interventions.	 Since	 this	was	a	 study	 in	young	girls	 seeking	 to	prevent	pregnancy,	there	was	no	washout	period	as	 the	risk	 for	unintended	pregnancies	during	wash	out	was	 high.	 However,	 intraindividual	 analysis	 looking	 within-person	 provided	participants	 to	 be	 their	 own	 control	 minimizing	 natural	 variation,	 and	 allowing	evaluation	of	longitudinal	changes	from	baseline,	which	further	confirmed	some	of	the	alterations	 seen	with	 the	use	of	NuvaRing	 compared	 to	NET-EN	and	COCPs.	Although	these	sexually	active	adolescent	girls	were	past	menarche	and	not	in	their	early	tanner	stages,	 having	 older	women	 as	 a	 reference	would	 have	 helped	 explain	 some	 immune	changes	 observed	 in	 this	 study.	 Other	 limitations	 included	 a	 small	 sample	 size	 and	adolescents	being	only	on	two	out	of	the	three	HCs.	Future	studies	should	aim	to	recruit	contraceptive	naïve	women,	and	have	each	participant	on	all	the	HC	options.	Recruiting	HC	naïve	adolescent	girls	would	help	to	link	changes	seen	to	the	use	of	HCs.			
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6.3 Conclusion		In	 summary,	 the	presented	data	 suggests	 that	HCs	appear	 to	 alter	 cervical	Th17	 cells	and	CD8+	T	cells,	while	only	NuvaRing	had	elevated	Th17-related	cytokines.	This	adds	to	the	body	of	evidence	on	the	biological	effect	of	progestins	on	vaginal	 immune	cells,	more	 importantly	 in	 adolescent	 girls	 who	 are	 one	 of	 the	 HIV	 key	 populations.	 The	dramatic	 changes	 of	 Th17	 and	 Tc17	 cells	 in	 addition	 to	 Th17-related	 cytokines	 seen	with	the	use	of	NuvaRing	warrants	further	investigation	of	potential	mechanisms.	Using	a	 placebo	 copolymer	 evatane	 vaginal	 ring	 and	 another	 silicon	 vaginal	 ring	may	 help	delineate	 how	 the	 hormonal	 and	 mechanical	 components	 of	 the	 CCVR	 impact	 the	vaginal	immune	microenvironment.																												
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		 NuvaRing	(n=34)	 NET-EN	(n=34)	 COCP	(n=37)	 	Kruskal	Wallis	 NuvaRing	vs	NET-EN	 NuvaRing	vs	COCP	 NET-EN	vs	COCP		 	 Median	and	IQR	 	 																											P-value	Produced	by	Th17	cells	 	 	 	 		 Adj.	 	 Adj.	 	 Adj.	 	 Adj.	IL-17A	 3.24	(0.91	-	7.69)	 1.05	(0.62	-	2.50)	 1.48	(1.01	-	2.24)	 0.029	 0.185	 0.009	 0.135	 0.110	 0.196	 0.225	 0.970	IL-17F	 6.83	(0.34	-	23.86)	 0.34	(0.34	-	10.80)	 0.80	(0.34	-	10.14)	 0.090	 0.192	 0.033	 0.142	 0.118	 0.196	 0.658	 0.970	IL-21	 12.12	(3.75	-	23.59)	 4.51	(0.01	-	16.10)	 7.22	(2.35	-	11.43)	 0.060	 0.185	 0.039	 0.142	 0.049	 0.147	 0.519	 0.970	IL-22	 9.22	(4.57	-	21.83)	 7.00	(4.05	-10.81)	 6.43	(4.32	-	11.73)	 0.363	 0.161	 0.173	 0.196	 0.285	 0.328	 0.852	 0.970		 	 	 	 		 	 	 	 	 	 	 	Differentiation	of	Th17	cells	 	 	 	 		 	 	 	 	 	 	 	IL-6	 3.43	(0.69	-	28.10)	 1.01	(0.17	-	13.56)	 1.01	(0.36	-	6.51)	 0.074	 0.185	 0.076	 0.483	 0.030	 0.147	 0.943	 0.970	IL-1β	 61.12	(2.70	-	152.0)	 10.68	(0.25	-	76.34)	 11.32	(0.36	-	56.51)	 0.067	 0.185	 0.061	 0.142	 0.032	 0.147	 0.970	 0.970	IL-23	 4.56	(0.12	-	13.27)	 3.99	(0.12	-	11.43)	 0.59	(0.12-9.54)	 0.408	 0.408	 0.387	 0.142	 0.184	 0.243	 0.735	 0.970	IL-33	 8.51	(3.43	-	22.19)	 3.50	(0.23	-	10.13)	 3.65	(1.08	-	9.84)	 0.066	 0.185	 0.034	 0.142	 0.063	 0.156	 0.605	 0.970	TNF-α	 1.21	(0.29	-	6.69)	 1.38	(0.03	-	3.62)	 0.32	(0.13	-	2.41)	 0.177	 0.279	 0.344	 0.396	 0.045	 0.147	 0.583	 0.970		 	 	 	 		 	 	 	 	 	 	 	Regulators	of	Th17	cells	 	 	 	 		 	 	 	 	 	 	 	IL-4	 0.52	(0.05	-	5.42)	 0.05	(0.05	-	1.38)	 0.05	(0.05	-	1.51)	 0.170	 0.279	 0.074	 0.142	 0.168	 0.243	 0.777	 0.970	IL-10	 0.31	(0.01	-	1.81)	 0.01	(0.01	-	1.17)		 0.01	(0.01	-	0.56)	 0.186	 0.279	 0.483	 0.483	 0.073	 0.156	 0.248	 0.970	IL-25	 0.37	(0.01	-	1.51)	 0.01	(0.01	-	0.62)	 0.01	(0.01	-	0.45)	 0.067	 0.185	 0.059	 0.142	 0.037	 0.147	 0.817	 0.970	IL-31	 54.09	(19.30	-	108.10)	 26.63	(17.14	-	61.97)	 34.99	(21.03	-	65.77)	 0.272	 0.358	 0.131	 0.196	 0.360	 0.370	 0.373	 0.970	IFN-γ	 2.95	(1.21	-	8.73)	 2.25	(0.51	-	3.99)	 1.81	(0.84	-	4.03)	 0.347	 0.388	 0.226	 0.282	 0.195	 0.243	 0.947	 0.970	sCD40L	 6.70	(0.07-11.93)	 0.07	(0.07	-	8.90)	 0.32	(0.13	-	2.41)	 0.286	 0.358	 0.121	 0.196	 0.370	 0.370	 0.447	 0.970	Intention	to	treat	analysis	(ITT).	P-value	adjusted	(Adj.)	using	the	Benjamini-Hochberg.	
